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Abstract 
Background: 
Medical products (encompassing medicines and medical devices) are critical health system 
building blocks; access to medical products (ATM) impact clinical outcomes.  However, cost 
and operational inefficiencies in the health system limits ATM.  Funding strategies and policy 
reforms are key instruments in managing the supply and demand side determinants of ATM.   
Objectives: 
This study aimed to 1) analyse the  South African(SA) regulatory framework for medical 
products; 2) review expenditure on medical products at Private, Public and Household levels; 
and 3) describe ATM using the WHO Building Blocks framework and 4) gauge the status of 
supply and demand side determinants of ATM. 
Methodology: 
A mixed methods study design was used to represent ATM complexity in the health system. 
USAID’s Health System Assessment Approach was used to analyse the enabling legislative 
and regulatory landscape for ATM in SA. Unpublished National Treasury, provincial 
Departments of Health and Council for Medical Schemes Annual Reports were sources for the 
descriptive trend analysis of public and private sector medical products expenditure. 
Household out-of-pocket expenditure was analysed from Statistics SA national household 
survey data. With data from key informant interviews, a systems diagram was constructed.  
District Health information system and national survey data was used to present current system 
performance using supply and demand side indictors of ATM.   
Results: 
Medical products expenditure is a major cost driver in the private sector.  Households with 
medical aid, spent more OOP on medical products than the uninsured; province, household 
size and income sources were not significant factors in estimating medical products 
expenditure. In the public sector, trends demonstrate increasing investment in medical 
products, however indicators of supply side ATM determinants show poor performance.  In 
2014, health contributed 0.9 %( R935) of total household expenditure; which does not 
constitute catastrophic expenditure levels. A larger proportion of total health spending is on 
medical products (0.7%) than outpatient medical services (0.6%) in average SA households; 
pharmaceutical expenditure dominates (90%) compared to therapeutic appliances and other 
medical products combined (10%). In uninsured households NC and LP provinces and Indian 
and White population groups were the only statistically significant variables in estimating 
expenditure. Male headed households spend more actual Rands on medical products than 
female headed households. A R31.00 decrease in expenditure for rural insured households 
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was calculated for each increase in expenditure by urban insured households. Households in 
FS, NW, EC and NC had the highest OOP expenditures on medical products. Households in 
LP had the lowest OOP expenditure on medical products in the survey period.  
Conclusions and Recommendations: 
There are opportunities in the scale up to UHC to implement policy options to increase ATM. 
Capacity building is needed to ensure equitable fiscal allocations, ability to absorb resources 
and optimise service delivery within government.  Need for improved monitoring and data 
analytics of cost, access and utilisation of medical products at public health facilities; OOP 
spending on medical products in private sector in terms of outpatient and hospitalisation and 
survey data at household level spending. Managed care Organisations can contribute to ATM 
through quality and clinical governance in the private sector. 
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Glossary 
Medical device 
“Medical device” means any instrument, apparatus, implement, machine, appliance, implant, 
reagent for in vitro use, software, material or other similar or related article including Group III 
and IV Hazardous Substances contemplated in the Hazardous Substances Act, 1973 (Act 
No. 15 of 1973) — (a) intended by the manufacturer to be used, alone or in combination, for 
humans or animals for one or more of the following:  (i) diagnosis, prevention, monitoring, 
treatment or alleviation of disease; (ii) diagnosis, monitoring, treatment, alleviation of or 
compensation for an injury; (iii) investigation, replacement, modification, or support of the 
anatomy or of a physiological process; (iv) supporting or sustaining life; (v) control of 
conception; (vi) disinfection of medical devices; or (vii) providing information for medical or 
diagnostic purposes by means of in vitro examination of specimens derived from the human 
body; and (b) which does not achieve its primary intended action by pharmacological, 
immunological or metabolic means, in or on the human or animal body, but which may be 
assisted in its intended function by such means(1).   
In Vitro Medical Devices (IVD) 
‘In Vitro Diagnostic (IVD)  means a medical device, whether used alone or in combination, 
intended by the manufacturer for the in-vitro examination of specimens derived from the 
human body solely or principally to provide information for diagnostic, monitoring or 
compatibility purposes(1).  
Medical equipment 
Medical devices requiring calibration, maintenance, repair, user training and 
decommissioning – activities usually managed by clinical engineers. Medical equipment is 
used for the specific purposes of diagnosis and treatment of disease or rehabilitation 
following disease or injury; it can be used either alone or in combination with any accessory, 
consumable or other piece of medical equipment. Medical equipment excludes implantable, 
disposable or single-use medical devices(1). 
Consumables medical supplies 
Non-durable medical supplies that are  usually disposable in nature; cannot withstand 
repeated use by more than one individual; are primarily and customarily used to serve a 
medical purpose; generally are not useful to a person in the absence of illness or injury; may 
be ordered and/or prescribed by a physician(2). 
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Health technology 
Refers to the application of organised knowledge and skills in the form of (medical) devices, 
medicines, vaccines, procedures and systems developed to solve a health problem and to 
improve quality of lives. (WHA 60.29)(1)  
Medical products / Health products 
Products used for health related matters may be categorised into two major categories 
according to intent, i.e. those which aim to diagnose, to treat and to prevent disease and 
injury; and general health and wellness products. Health products which aim to diagnose, to 
treat and to prevent disease and injury include all medicines (allopathic and complementary) 
and medical devices (including in vitro diagnostic devices, IVDs). The regulation of safety 
and efficacy of medicines is well established for allopathic medicines and recently initiated for 
complementary medicines(3) 
Medicine / Pharmaceutical / Drug 
 “Medicine” (a) means any substance or mixture of substances used or purporting to be 
suitable for use or manufactured or sold for use in — (i) the diagnosis, treatment, mitigation, 
modification or prevention of disease, abnormal physical or mental state or the symptoms 
thereof in humans; or (ii) restoring, correcting or modifying any somatic or psychic or organic 
function in humans, and (b) includes any veterinary medicine(4).  
COICOP (classification of individual Consumption According to Purpose) codes (5) 
Medical Products, Appliances and Equipment   
This group covers medicaments, prostheses, medical appliances and equipment and other 
health-related products purchased by individuals or households, either with or without a 
prescription, usually from dispensing chemists, pharmacists or medical equipment suppliers. 
They are intended for consumption or use outside a health facility or institution. Such 
products supplied directly to outpatients by medical, dental and paramedical practitioners or 
to in-patients by hospitals and the like are included in outpatient services (06.2) or hospital 
services (06.3). 
Pharmaceutical products 
Medicinal preparations, medicinal drugs, patent medicines, serums and vaccines, vitamins 
and minerals, cod liver oil and halibut liver oil, oral contraceptives. Excludes: veterinary 
products (09.3.4); articles for personal hygiene such as medicinal soaps (12.1.3). 
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Other medical products  
Clinical thermometers, adhesive and non-adhesive bandages, hypodermic syringes, first-aid 
kits, hot-water bottles and ice bags, medical hosiery items such as elasticated stockings and 
knee supports, pregnancy tests, condoms and other mechanical contraceptive devices. 
Therapeutic appliances and equipment    
Corrective eyeglasses and contact lenses, hearing aids, glass eyes, artificial limbs and other 
prosthetic devices, orthopaedic braces and supports, orthopaedic footwear, surgical belts, 
trusses and supports, neck braces, medical massage equipment and health lamps, powered 
and unpowered wheelchairs and invalid carriages, ‘‘special’’ beds, crutches, electronic and 
other devices for monitoring blood pressure, etc.; – repair of such articles. Includes: dentures 
but not fitting costs. Excludes: hire of therapeutic equipment (06.2.3); protective goggles, 
belts and supports for sport (09.3.2); sunglasses not fitted with corrective lenses (12.3.2). 
Outpatient Services  
This group covers medical, dental and paramedical services delivered to outpatients by 
medical, dental and paramedical practitioners and auxiliaries. The services may be delivered 
at home, in individual or group consulting facilities, dispensaries or the outpatient clinics of 
hospitals and the like. Outpatient services include the medicaments, prostheses, medical 
appliances and equipment and other health-related products supplied directly to outpatients 
by medical, dental and paramedical practitioners and auxiliaries. Medical, dental and 
paramedical services provided to in-patients by hospitals and the like are included in hospital 
services (06.3). 
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CHAPTER 1: INTRODUCTION AND LITERATURE REVIEW 
 
1.1 Introduction 
Good health is important to build traditions and norms for communities to flourish (6). Today 
however, what resonates is the association of health and productivity as a means to achieve 
economic growth to improve lives in society(7).  Improving the health status of citizens is 
therefore a political and policy priority for South Africa.  The Bill of Rights  enshrined in the 
South African Constitution since 1996, recognises access to healthcare as a basic human 
right(8).  In realising this right, access to healthcare services and professionals  without  
medicines and medical devices (referred to as ‘medical products’)  is of little practical 
significance(9).  
Medical products save lives and help avoid catastrophic consequences to health status but 
they are expensive and need sustainable financing mechanisms to fund them consistently 
and reliably(9).  Literature on access to medical products  highlight  regulation and financing 
as key system inputs  in the value chain linking the pharmaceutical and health  technology  
industries to the health sector(10).    
Expenditure on medical products, pharmaceuticals in particular, is a major driver of cost for 
the State, after Compensation of Employees(11).  In 2016,   spending on medicines (R13bn) 
and medical supplies (R7bn) across all provinces in South Africa (SA) (12)  served an  
estimated  45 million uninsured individuals (81% of  total population) (9), who  rely on the 
public sector  to meet their healthcare  needs.  Medical products expenditure is also a  major 
cost driver of healthcare in the private sector, where ,  R23.9bn (15.84%) was spent  on 
prescribed medicines alone (13) in 2016 from total industry benefits paid (R151.21bn).  
In the context of overall health spending,  households in low and lower middle  income 
countries in Sub-Saharan Africa (SSA), incurred most (more than 85%) of total health 
expenses Out Of Pocket(OOP) in 2009; the main expense (50 to 80%) of total spend  is on 
medicines (14).  Despite this, allopathic medicines are estimated  to be underfunded in both 
public and private (about 20% overall expenditure) sectors in LMICs in 2004 (15).  
Recognising the resource limitations and capacity constraints in South Africa, effective 
medical treatment and intervention demands innovative financing strategies and responsive 
health delivery systems (9).  There is increasing demand and dependence on medicines in 
clinical practice brought about by increases in population size and life expectancy.  
Innovative new drug formulations present novel treatment modalities, but are expensive new 
market entrants.  As multimorbidity increases, combination replaces monotherapy and acute 
episodic treatment is replaced by chronic management (9).  
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Access to medical products (ATM) is an essential part of the health service delivery but 
suffers the tensions between underfunding and overspending; medicines selection and 
rational use; pricing and cost; efficient supply and effective demand management (9). There 
are serious gaps in knowledge of financing and expenditure in medical products in SA 
although accessible and publicly available information is reported by public and private 
sectors and gathered from households routinely (30).  Although pharmaceutical policy 
analysis and reviews have been undertaken in SA, more research is needed to define ATM 
within the context of the health system (98,132).  This study critically reviews the literature on 
policies, laws and regulations that frame the interaction between the health technology 
industry and the health sector in South Africa and analyses the financing and expenditure of 
medical products, with a specific focus on allopathic medicines, in the health sector (public 
and private) and at household level.  Linking the analyses, the health systems approach 
contextualises the discussion of ATM in South Africa.    
1.2 Background   
The anatomy of the clinical consultation has evolved to an extent where medical products are 
now indispensable in the encounter(9)and this is true also for allied health professions.  
Medical products can be defined within a broader framework of health technologies shown in 
Figure 1.  The Medicines and Related Substances Control Act (1965) (referred to as ‘The 
Medicines Act’) and the Amendments, form the regulatory basis for all aspects of health 
technology in South Africa.  The most recent Amendments (2008 and 2015) introduce 
medical device, complementary and traditional medicine regulation in South Africa(4).    
Precise and consistent technical definitions are critical to classify health technologies 
according to risk and intended use,  which  determines applicable regulatory controls(1) .  
Although health technology  encompasses blood products and Advanced Therapeutic 
Medicinal Products (ATMPs)(1) , which are innovative new therapies such as gene, tissue 
and cell technologies(146),  these are considered beyond the scope of this study and have 
been omitted in the analysis.    
Medical products introduce technical and economic challenges to health systems and raise 
concerns around sustainable financing, efficiency and equity.  Harmonising regulatory 
requirements can decrease costs of compliance and product registration time, enabling 
faster access to medicines and medical devices, ultimately benefitting users(16).    
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Figure 1 : Interrelation of medical products inside and outside healthcare 
Source: Medicines Control Council, Borderline Products 2017(3) 
 
A demonstration of the impact of ATM in the lives of South Africans, is the historical 
pharmaceutical industry action against the South African government’s intention to provide 
access to lifesaving Antiretrovirals (ARVs).  Pharmaceutical Manufacturers in SA sought to 
oppose  parallel importation of low cost  generics and manufacturing licences under the 
provisions of Section 22C in the Medicines’ Act,  for local generic manufacturing  (17,18). In 
1991, the average annual cost of (ARV) triple therapy per patient in Africa was approximately 
USD 12 000.  Through cooperative agreements between industry and government, annual 
costs of ARVs fell to less than USD 1000 in 2003.  This improved access to ARVs lead to 
increases in  life expectancy at birth for  South Africans from 54.9years in 2002  to 64yrs in 
2017  (19).   With an estimated 6.4 million people living with HIV/AIDS  in South Africa in 
2012 (20)and 7.52million in 2018(147), ATM requires  an integrated  health systems 
response with costly, resource- heavy inputs from service delivery, finance, human 
resources, health information  and governance building blocks(21, 9).  
The first South African National Drug Policy (NDP) in  1996 addressed health inequities and 
improved access to medicines for all South Africans, recognising the disparities between the 
consumption in the larger public (70% volume) and private (80% expenditure) in health 
sectors (22).  In three decades of implementing National Medicine Policies (NMPs) across 
the globe, evidence points to policy and regulation  as  effective instruments  to improve 
access, control expenditure, rationalise use and ensure quality of medicines(9).   Where 
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health sector equity, social justice and service orientation  converges with industry  and 
market agendas ,  vulnerability to fraud, mismanagement, patent law infringements, 
information asymmetry and corruption pose real threats(9).  Amartya Sen in Ruger’s “Health 
and social Justice“  recognises the role of public policy across sectors to promote health, 
aligned with the World Health Organization’s (WHO)  “health-in-all-policies” approach (23).  
WHO-supported global policy changes have resulted in ATM increases from around 2.1 bn 
(1977) to an estimated 3.8 bn people(1997) (24).   About fifty percent of the population in 
parts of Africa and South-East Asia in 2002 lacked access to essential medicines. The 
Report of the Commission on Macroeconomics and Health (2001) estimated that by 2015 
over 10 million deaths per year could be averted by ensuring ATM(25).However in 2015,  
United Nations(UN)  MDG target 8E progress reports (“In cooperation with pharmaceutical 
companies, provide access to affordable essential drugs in developing countries”) found that 
low availability, high prices and poor affordability of medicines are still key impediments to 
treatment access in LMICs (26). WHO  estimates that nearly two billion people (a third of the 
world’s population) still do not receive a regular and consistent supply of crucial medicines in 
2015 (27). 
Beran et al suggest  that increasing expenditure is an effective policy instrument to improve 
health outcomes, but cannot be successful without health systems strengthening(28). 
Several studies confirm that increased financial investment results in positive health 
outcomes in Africa (7,29,30,31) .  Others argue that increased spending alone cannot not 
improve access emphasizing Social Determinants of Health (SDH) such as income per 
capita, income distribution, female education levels, ethnic fragmentation and religion, have 
profound effects on health outcomes(32,33).  Increasing life expectancy and paradoxical 
increases in morbidity from a high burden of NCDs and chronic infectious diseases (e.g. HIV 
and TB) impact health policy and financing decisions.  The epidemiological profile of the 
country should be a key determinant in funding decisions  allocating equitable financial 
resources to greatest need(32).  South Africa and other  Low and Middle income countries 
(LMICs) share a high burden of disease which affects ATM in a variety of ways such as:  
differential access to acute and  chronic medications;  high demand in public sector;  high 
cost in  private sector;  wide contrasts in patient experiences afforded by insurance coverage 
and geospatial health service delivery arrangements (33,34,35). 
The literature review describes ATM using the health systems approach, to address barriers 
to access, discussing the relevance of emerging challenges in health policy and financing.   
Research suggests that access to health services has improved over the past two decades 
in South Africa however,  a deeper understanding of  service quality  is needed to inform an 
appropriate  systems and policy response(36).   Therefore, the aim of the literature review is 
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to provide a critical analysis of access to medical products in health systems and highlight 
the links between policy, financing and ATM in South Africa.   
 
1.3 Defining ‘access to medical products’ in the South African context  
‘Access to medical products’ is defined as “having medicines continuously available and 
affordable at public or private health facilities or medicine outlets that are within one hour’s 
walk of the population”(37).  Medicines in this context refers to pharmaceuticals or drugs and 
do not encompass complementary and traditional medicines(1,4).Most definitions recognise 
the role of  time, distance, resources involved in seeking health care(38,39).  Access is 
therefore multidimensional and complex which makes measurement complicated. 
Enrolling patients onto treatment may improve coverage or uptake of services but without 
improvement in health outcomes it is not considered ‘accesses.   ATM therefore implies that 
individuals should possess both the ability and resources to obtain medicines when they are 
needed, to improve health. Although Penchansky and Thomas introduced  five dimensions 
for access(40) in healthcare  in 1981, most current descriptions emphasizes four dimensions: 
accessibility , affordability, availability, and acceptability(9, 41,42,43). Beran et al distinguish  
ATM  from access to treatment by emphasizing the role of other health systems determinants 
such as infrastructure, health worker expertise, adequate funding of resources and poor 
information management(28), a burden experienced disproportionately in LMICs.   ATM is 
therefore, inextricably linked to access to healthcare and is the premise on which this study is 
based.  
‘Access to care’ viewed from the demand side perspective, is the empowerment or ability of 
an individual to use healthcare resources  and represents an interaction between  
individuals, households,  the community and the healthcare system(43).  The 70th World 
Health Assembly (WHA) in 2017, refers to supply side definitions of ATM  as multistage 
processes along the medical products  value chain from “needs based research, 
development and innovation;  quality manufacturing processes ;  public health- oriented 
intellectual property and trade policies; selection, pricing and reimbursement policies; 
integrity and efficiency of procurement and supply; and appropriate prescribing and use”(44).  
 
1.4 Health systems approaches to ‘Access to medical products’    
There is universal acknowledgement of the impact of ATM in health systems.  The 
Sustainable Development Goals (SDG 3) and its predecessor, Millennium Development 
Goals (MDG 8) recognised the impact of ATM on the global health agenda.  The UN  ‘High-
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Level Panel on Access to Health Technologies’(44) in 2016, called for new approaches to  
health technology innovation, ensuring access that  benefits all people.  The 70th World 
Health Assembly in 2017 drew attention to the “global shortage of and lack of access to 
medicines and vaccines” despite the importance of ATM underlying public health strategies 
(44).     
The health systems approach favours the utility of frameworks to describe complex 
environments, highlighting interactions between elements.  The WHO Framework for Action 
(2007) (45) listed priorities for countries in ensuring ATM, focussing on overall health 
systems performance at a macro level.  The framework emphasizes interaction of the six 
building blocks in strengthening health systems.  The WHO Access  framework (2004) (24), 
which pre-dated the health systems strengthening  agenda of the 1990s,  focusses on 
supply-side policy  reforms .  Four themes introduced here (rational use, sustainable 
financing, affordable prices and reliable health  and supply systems) are incorporated  in the 
Management Sciences for Health (MSH) Centre for Pharmaceutical Management (CPM) 
(2011)  Framework (9). 
The conceptual framework for assessing access to health services by Peters et al(42) in 
Figure 2 reinforces the relationship between quality and access to healthcare.  The model 
recognises the influence of policy on the macro-context, showing the effects of illness on 
poverty and vulnerability.  In this model, the supply and demand side dimensions of access 
create a measurement matrix for efficiency and performance.  The MSH/CPM model for ATM 
adds the domains of quality (safety, efficacy and cost effectiveness) as an essential cross-
cutting attribute of medical products. Access is seen as the result of the interaction of 
finance, information, service delivery, and governance building blocks in the health system 
(98). 
Levesque’s conceptual framework maintains the integrity of the access dimensions seen in 
other models but focuses on SDH. This model highlights  the interface between user and 
health service along a pathway beginning with the user’s capacity to convert a health need  
into a demand for service termed  ‘expressed utilisation’.  Here access is the final outcome, 
contingent on the user’s capacity to navigate and negotiate barriers to access(46) .     
Viewed as a whole, the conceptualisation of access to healthcare and extensibly ATM is 
consistent across many models. Embedding ATM models  within the health systems 
frameworks, based on evidence from successfully implemented programs, provides policy 
makers and health officials the knowledge base from which  to identify leverage points for 
action (47).  When the model is sufficiently robust, decision makers at different levels can 
interpose local knowledge and extrapolate results within defined system parameters, if they 
are able to assimilate their own capabilities within health system components (48).  Effective 
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policies catalyse people and relationships in the system to act as inhibitors or enablers which 
transform organisational capacity on the supply side.  This can greatly influence availability 
and acceptability (demand side) of ATM (48).   The impact and consequences of equity, 
social justice, innovation, globalisation and politics , should inform ATM  public health 
program design and goal setting (48).    
Advocated by WHO for LMICs, Universal health coverage (UHC) goals of equity, financial 
risk protection and access to a comprehensive range of services, have proven elusive thus 
far. The NHI currently being implemented in South Africa, principled on risk sharing and 
cross subsidization, relies on a high degree of social solidarity which is questionable with 
historical and current untenable  levels of inequality (49).  Within-country differences such as 
decreased poverty levels, higher medical scheme membership and increased per capita 
health spending in Gauteng and Western Cape as compared to Limpopo and Eastern Cape 
exacerbate inequity(59,86,57,60).  Equitable ATM is therefore, an appropriate goal within the 
South African setting(42).  
 
1.5 Health systems assessment of ‘Access to medical products’   
Defined by the WHO, “Health is a complete state of physical and mental wellbeing not merely 
the absence of disease or infirmity“(50).  In this sense, ‘health’ is defined as an outcome and   
healthcare is a determinant of health. Here, ‘healthcare’ refers to services delivered to either 
the public at large (e.g. campaigns for health promotion) or personal health services (clinical 
consultation and treatment).  Health systems represent the structures, resource mobilisation 
and actions which influence health (outcome).  In this study, ATM is viewed as an outcome. 
This outcome (ATM) is a product of the performance of the healthcare system.  Thus, to 
assess healthcare performance, an evaluation of the delivery mechanisms of health services, 
is needed(51).  
The extent to which access is achieved can be assessed through utilisation, patient 
satisfaction and extent of changes to service provision.  ‘Access’ and ‘coverage’ have been 
used interchangeably to describe measurable targets of health system performance. 
Epidemiologists aspire to achieve maximum  ‘coverage’  of an intervention in a target 
population; policy makers aspire towards achieving access to healthcare for an entire 
population(45).  Given its complexity, an overall picture of access to medicines can be 
generated using a range of indicators that provide data on medicine availability and price, in 
both public and private sectors, in combination with key policy indicators. 
Measurement guides improvement  in health systems(52) which is required to address ATM 
shortcomings in South Africa.  Quality data enables decision-makers to assess ATM and 
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make informed decisions to intervene.  Monitoring of availability, quality and misuse of 
medical products can facilitate timely intervention and improve ATM.   WHO  supports  the 
development and use of practical indicators, methods and systems for monitoring access to 
medicines and the use of this  data to adapt and amend policies and practice but much more 
needs to be done to achieve this to fulfil the reporting requirements for the SDG 3.8 (53) 
Survey data has also been used successfully to analyse access to health(54).    
ATM can be measured in four dimensions; accessibility, availability, affordability and 
acceptability, each with demand and supply side determinants.  A study of access to General 
Practitioner (GP) primary health care (PHC) services in Australia singled out Acceptability 
(patient preference) and Availability (GP) as the most important dimensions(55).     
In 1993, Institute of Medicine (IOM) set up a gauge for access to healthcare consisting of 
routinely collected information in the health system, tracked over time, providing a realistic 
impression of progress for policy and decision makers.  The diagram below by Peters et 
al(42) provides a conceptual framework of practical utility in measuring access to health 
services.   Factors affecting access to healthcare and ATM are closely linked and reflective 
of common systemic issues (52,56,28) and are therefore  considered synonymously in this 
study.   
 
 
Figure 2: Conceptual framework used to assess health service 
Source: Peters et al. (55) 
 
The Peters et al. model combines supply and demand determinants of access to healthcare 
in the context of poverty and has utility for describing ATM in SA.  Demand side determinants 
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of access are subject to differences in decision-making and health seeking behaviour at 
individual and community level;   individuals make choices about their health and 
communities make decisions based on resources. However, an exploration of these factors 
at an individual level affecting behaviour, preference and choice are beyond the scope of this 
study.  
Accessibility is defined as the geographic location or travel distance from or to a service 
delivery point(46).  The South African Health and Demographic Survey (SADHS) in 2003 
found that women of all ages, experienced problems accessing care. Two of the top three 
commonest barriers to access healthcare across all provinces and in all race groups was due 
to reliance on transport (31.8%) and distance (30.6%).  The SADHS found that women living 
in Limpopo Province (LP) and those with children were particularly vulnerable to impeded 
access. This has deleterious effects on health status of mother and child as it impacts on 
uptake of immunisation and antenatal care(57). McIntyre and Ataguba (43) suggest  that 
physical access to health facilities leads to increased utilisation of services which  improve 
health outcomes. In 2008, the majority of South African households in urban areas (urban 
formal 52.4% and urban informal 53.4%) lived within a 2km radius of a health facility, except 
in traditional and formal rural areas, where most (64.3% and 76.3% respectively) lived more 
than 10km from a clinic(107, 56).   However, the 2016 SADHS survey findings suggest that 
measures of access are shifting: women from non-urban areas were more likely to receive 
antenatal care from a skilled provider (96% vs 92%) as well as four or more ANC visits (80% 
vs 73%) than urban women (148).  
Availability is the ability to receive the appropriate services when the need arises.  From a 
user perspective, it refers to the appropriate type of care available to those who need it, such 
as hours of operation and waiting times that meet demands of users, as well as having the 
appropriate type of service providers and materials(46). Poor and inconsistent availability of 
medicines have immediate effects: inconvenience, actual and opportunity costs, no 
medication, incomplete regimen, less than required volumes and more burdensome 
alternatives. However the long term consequences are worse: incomplete vaccination 
schedule; treatment failure; catastrophic health expenditure and propagation of disease in 
the community(59).   
Measures of Availability are:  first point of contact for medical assistance; operating hours of 
facilities; waiting period (demand side) and medicine stock- out rates (supply side). In SA, 
public sector facilities continue to experience stock-outs of EML drugs.   The “Stop Stock 
Outs” campaign organised by a consortium of 6 civil society organisations report serious 
stock outs of EML drugs (especially HIV/TB drugs ) in PHC facilities across SA.    Seventy 
percent of these stock outs last for more than a month.  Routine paediatric vaccines were out 
of stock in 11% of facilities.   Stock outs in PHC facilities increased from 2014 (25%) to 2015 
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(36%)(59).  The District Health Information System (DHIS) data reflects that 78.4% of PHC 
facilities nationally had access to 90% of tracer medicines between 2016 and 2017(60). 
Although the requirement is to stock 90% of tracer medicines, only six districts were able to 
achieve this benchmark(60).  Globally, the average public sector availability of generic 
medicines ranged from 29·4% to 54·4% across WHO regions(61).  In the formal sector of 
LMICs, average availability of medicines is 35% in public facilities and 66% in the private 
sector, although prices are often unaffordable in the latter (62). 
Affordability describes both the price of services (supply side) and the willingness and ability 
of users to pay for those services (demand side).  Measures of affordability are users’ 
expenditure threshold for use of services and household expenditure on medical products.  
The SADHS in 2003 found that, on average, women of all ages, race groups, provinces, 
regardless of marital status and education level, cited affordability as the biggest barrier to 
accessing healthcare.  Limpopo province, rural settlement areas, Black African race group,  
no exposure to formal education, divorced or separated or widowed status, were positively 
associated with lack of access due to low affordability(57). However, by 2016, the GHS 
showed that affordability did not feature in the commonest causes of dissatisfaction among 
healthcare users (139).  
Acceptability, from a health systems perspective, reflects the extent to which the health 
service and professionals cater to individuals’ and communities’ social and cultural 
expectations. Measures of acceptability are cleanliness of facilities;  friendliness of staff and  
service satisfaction  visit to a health facility (63).  By these measures, the GHS 2016 found 
that service satisfaction and friendliness of staff were common reasons for patient 
dissatisfaction (139). Acceptability of medicines refers narrowly to the  “overall ability of the 
patient and caregiver (defined as ‘user’) to use a medicinal product as intended (or 
authorised)” (64)and is not explored in this work.  
 
1.6 Factors affecting ‘Access to medical products’ in South Africa    
South Africa, among  other LMICs,  is  experiencing an epidemiological transition  as the dual 
chronic infectious disease epidemic of HIV/AIDs and TB is gradually being replaced by 
chronic diseases of lifestyle as leading causes of morbidity and mortality(65) . Sixty five 
percent (65%) of mortality in persons over the age of 45yrs was attributed to NCDs in 2012. 
Despite the effects of HIV/AIDS, life expectancy  for South Africans at age 60 was 18.2yrs in 
2012 (66). Globally, between 1950 and 2017, life expectancy increased from 48·1 years 
(46·5–49·6) to 70·5 years (70·1–70·8) for men and from 52·9 years (51·7–54·0) to 75·6 
years (75·3–75·9) for women (149). Increasing longevity coupled with increased NCD 
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mortality and morbidity is expected to challenge existing models of healthcare provision and 
pharmaceutical utilisation and creates the opportunity for innovative approaches to ATM. 
Infectious disease epidemics such as Ebola and Zika viral outbreaks, exposed the 
heightened vulnerability of health systems responses across the globe. The WHO’s response 
procedure, Emergency Use Assessment and Listing (EUAL)  fast tracks access to 
diagnostics, medicines and vaccines in public health emergencies. As a longer term strategy,   
WHO- African Caribbean and Pacific Group of States Secretariat (ACP) –European Union 
(EU) collaboration has the task of expanding access and availability, improving quality and 
safety, and supporting good governance in the pharmaceutical sector. Participation in 
regional and international collaborative efforts are going to be key towards a harmonised 
response to health systems challenges especially in LMICs(67).  
Ethical issues in ATM surface at all levels where industry imperatives meet the public health 
agenda.   Following the South African-turned-global  controversy of  drug patents and high 
pharmaceutical prices  inhibiting access to life saving ARVs(68), the ethics of ATM has 
emphasized the need for policy and regulation of all health technologies .  Ethical concerns 
range from poorly evidenced claims of  effectiveness  in product registrations by global 
companies, incentives to providers  and professionals for selection and use of originator 
brands and specialised drugs or choice of health program (WHO Option A , B , B+ for the 
national PMTCT program) (67,68).   
MDGs are not devoid of ethically charged concerns- speculation on the reasons for dropping 
MDG 8,  which deals with facilitating ATM in developing  countries  through negotiation with 
pharmaceutical companies, suggest that the balance of power  and politics  were tipped(71).  
At a service delivery level, private providers may suffer the symptoms of poor regulation such 
as perverse incentives, unethical marketing, sampling and conflict of interest.  Over-servicing 
of ageing or terminally ill members of medical schemes involves spiralling costs (72) 
involving pharmaceutical and surgical modes of treatment.  Increased regulation is an 
effective tool to guide ethical practice in the health technology sector.       
 
1.7 Effect of policy on ‘Access to medical products’ in South Africa  
The nexus between the global health technology industry and the health sector is complex 
and serves important but diverse functions.  The aim of State intervention through health 
policy and regulation is to align the actions of a network of intersectoral stakeholders, with 
nuanced perspectives, towards improving ATM.  The objective of the global pharmaceutical 
industry is to innovate for profitability, market expansion and shareholder value.  These 
divergent mandates are in conflict when the right to health is poised against access based on 
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high costs of drugs.  The interaction of the health sector  (public and private) with the health 
technology  industry  requires a unified  robust  governance framework consisting  of 
legislation, regulation and policies in financing, human resources, service delivery and 
information system components.  A summary of the applicable regulatory documents is given 
in Appendix A.  In high income countries, medical product pricing and affordability 
predominate the policy direction. However, in LMICs  with fragile heath systems, sustainable 
financing, selection ,  procurement,  service delivery and universal access issues dominate 
(73).  
Challenges with ATM in South Africa have been amplified by the media, social justice 
coalitions and the development sector by organisations (such as TAC, Section27, MSF, 
SAPAM, AMASA, SARAM and FTPL) (see Abbreviations) advocating change based on 
users’ experience of ATM.  These social coalitions are a powerful voice, setting the policy 
agenda in international trade and politics and acting as informal monitors of government 
performance in ATM as they raise the profile of citizens’ demands(66,68,72,73). 
The South African National Drug Policy (NDP) is  based on WHO guidelines for developing a 
national drug policy(76). The NDP spans two decades of transition and gives strategic 
direction, objectives and goals for the interaction of the health sector with the pharmaceutical 
and medical device industry.  The  United Nations Development Program (UNDP)  principles 
for good governance (Legitimacy and voice, Direction, Performance , Accountability and 
Fairness) forms the structural basis of the NDP  (77) in recognition of the vulnerability of this 
sector to unethical practice and corruption involving international, national and local entities .  
The SA NDP addresses the first 5 key  generic  elements of the WHO guidelines as shown in 
Table 1(9), and includes contextual  issues  that can be  addressed through policy. These 
elements are, by themselves, not sufficient to ensure ATM, but create the environment for 
stewardship, where all stakeholders can be held accountable.   
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Table 1 : Summary of South African National Drug Policy, 1996 
 Source: Author 
Pharasi and Miot’s reviews of medicines selection and procurement policies(78) suggest that 
South Africa has marked good progress towards implementing the health objectives of the 
NDP.  These initiatives include medicines formularies and treatment guidelines in the private 
sector, Prescribed Minimum Benefits (PMB) definitions, and criteria for the use of medical 
products and centralised procurement in the NDOH.  The extent of changes since NDP 
implementation has not been quantified although some independent efforts in 1998 (NDOH), 
2003 (Human Sciences Research Council (HSRC)) and 2005 (NDOH/MSH collaboration) 
were made to evaluate specific aspects of the policy.    Availability of medicines in PHC and 
reliable consistent supply of medical products continues to impact  service delivery(79). In 
2016, some medical device companies withdrew support to public sector citing payment 
delays and non-payment; corruption; and inconsistent tender practices.  As the device 
industry comprises mainly small to medium enterprises unable to absorb irregular payment 
cycles, the result is decreased competition among suppliers.  Heavy reliance on single 
suppliers interrupts regular supply and access to essential medicines. (80) 
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The cost- versus- access policy debate in medicines and healthcare has infiltrated the public 
domain domestically and abroad.  However, WHO’s Good Governance for Medicines (GGM) 
program claims that public access to information about pricing and quality in the 
pharmaceutical sector is lacking(81).  The ‘Medicines Act’ Amendment (2002), introduced 
new definitions in the pharmaceutical regulatory lexicon for licencing, pricing committee and 
marketing controls. Policy  initiatives targeted discriminatory practices, promotion of generics,   
rational drug use, single exit prices, fixed professional and dispensing fee regimens, 
regulatory  price increases and establishment of  clinical governance structures at service 
delivery levels as  Pharmacy and Therapeutics committee (PTCs) (82,87).  
Some of the most profound effects of policy changes since 1996 have been mandatory 
generic substitution augmented by local manufacturing capability.  One such estimate in 
2017, of the extent to which prices have dropped due to generics is 80% (83) However, there 
are claims  of transfer of perversity from doctor to pharmacist . Despite the establishment of 
the pricing committee and the price registry, a transparent pricing system and public 
awareness of medical product pricing is not optimally realised.  Control of rebates, discounts 
and bonuses has eliminated the rural-urban differentiated prices, prevented risk transfers by 
unit pricing and prevented bulk discounts for chain stores(84).  Single exit price policies(SEP)  
have yielded about a 19% drop in the price of medicines(85).  
There are some lingering concerns around aspects of implementation such as logistic fee 
controls, external reference pricing and incentive scheme controls. (86). In the public sector, 
the focus has shifted over the past two decades towards building capacity in the health 
system for ATM specifically through improved drug availability and rational use at service 
delivery level.  The Medicines Control Council (MCC), superseded by SAHPRA in June 2017 
has instituted a range of policies to address key issues in management of medical products, 
vaccines and technologies.   
The selection of medicines appropriate for SA has involved adoption and use of STG/EMLs 
as well as the development of national strategic plans for priority health conditions.  
Manufacturing, procurement and distribution such as software to manage stock, Central 
Chronic Medicines Dispensing and Distribution (CCMDD) programme, regulations of the 
Preferential Procurement Policy Framework Act by the National Treasury to align BEE to 
healthcare procurement, as well as allocation of products for local production.  Substantial 
investment has been made in the public sector by training cadres (pharmacy assistants, 
SCM, finance and clinical staff) at various interfaces of the pharmaceutical and medical 
supplies value chain to improve the process(87). 
The emergence of multidrug resistant healthcare associated infections (HAI) in South Africa 
is linked to increased costs and poor patient outcomes in both public and private sectors.(88)   
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Although the media discourse emphasizes the patient preference and palliation(89),  the role 
of expensive, aggressive treatment modalities, prolonged ICU and hospital stay , driving  
expenditure on medical products,  is  not clear .  Without new antibiotic compounds in the 
pipeline for the next two decades,  policies advocating rational use of available  drugs are 
critical in public and private sectors(90). More health systems and policy research (HSPR) 
and economic evaluations could be used to compare cost effectiveness of clinical 
interventions.   
Some newer cancer chemotherapy, orphan and specialised drugs, with contested clinical 
and cost effectiveness outcomes, are subjected to Managed Care Organisations (MCOs) 
evidence based rational drug use policies.  One such example is the oncology drug under 
the registered trade name “Herceptin”, which prompted debates on risk sharing and 
outcomes based reimbursement models between Pharma and Funders(91). In South Africa, 
more is known about  drug utilisation through research(92)  than through praxis(93). Systems 
for reporting drug utilisation are disparate and lacking within and across the public and 
private health sectors(94).  
Research in the pharmaceuticals sector in South Africa has focussed almost exclusively at 
discipline-level from  medicine(95) , pharmacology(96) , economics , law(18), industrial 
engineering (97) , health management(98) , health advocacy (75) and public health focussing 
on a wide range of policy areas .  Topic areas well represented by research are intellectual 
property, patent law, essential drugs, rational use, traditional medicines, procurement and 
supply chain for medical products, pricing and organisational capacity to regulate the 
pharmaceutical sector.  In the context of South Africa’s quadruple burden of disease, access 
to specific drugs such as ARVs, TB and oncology drugs have been studied from a clinical 
perspective(97,98)  Although some authors have addressed ATM in South Africa (100), few 
have presented it in relation to complex interactions of other health systems resources and 
therefore  less pragmatic and sustainable solutions to real world implementation challenges 
have been found.   Health Systems and Policy Research (HSPR) enables the ATM issue to 
be embedded within quality, resource planning and delivery debates on both supply and 
demand side of access. Within the current paradigm of reform towards UHC,  Gray and 
Suleman suggest that evidence of ATM experience from  LMICs should guide policy making  
in South Africa (101). To support this goal, a thrust of  HSPR  should be undertaken  in South 
Africa for fresh ATM perspectives within health  system complexities(48,101).  
The WHO GGF points to role of organisational capacity building for regulation in the crucial 
area of medicines pricing, selection and registration by statutory bodies at national level 
which is evident in South Africa.  Countries either lack policy initiatives or effective 
implementation or both(103).   
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This study presents a baseline assessment of pharmaceutical policy, regulation and laws 
using the Health System Assessment Approach (HSAA) as a guiding tool to gauge 
orientation to the ATM goal in South Africa.   A major objective of this study is to produce a 
health systems diagram for ATM in SA based on the literature and qualitative data analysis, 
demonstrating the multidimensional interactions of the building blocks.  The advantage of a 
health systems approach is to stakeholders who are able to identify their sphere of influence 
to leverage their contributions in strategic and sustained ways in the health system.  Effects 
of policy and intervention on system resources are also made clearer through this approach.  
Innovative delivery models for ATM in South Africa , coupled with a HSPR  flagstone, can 
have pragmatic implications for LMICs (73) .   
 
1.8 Funding of medical products in South Africa   
The new global medicines framework  “Towards Access 2030” by WHO and the Lancet 
Commission on ATM  calculates between US$77.4 and $151.9 billion per year (or $13 to $25 
per capita) is needed to provide a basic package of 201 essential medicines for all 
LMICs(44). In 2002, it was estimated that  over 70% of pharmaceuticals are publicly funded 
through reimbursement plans and other mechanisms in developed countries, in contrast to 
developing and transitional economies where 50 to 90% of medicines are OOP (25). In 
developing countries the budget for medicines corresponds to 24 to 66% of national health 
expenses, supporting the monitoring of access to medicines in these countries(27).  
A study of pricing and affordability in developing and middle income countries by Cameron et 
al (62) showed that median government procurement prices for generic medicines were 
similar to international reference price. However, low procurement prices did not always 
translate into low patient prices and treatment was still unaffordable in many countries.  
Private sector patients paid 9–25 times international reference prices for lowest-priced 
generic products and over 20 times international reference prices for originator products 
across WHO regions. In the private sector, wholesale mark-ups ranged from 2% to 380%, 
whereas retail mark-ups ranged from 10% to 552%(62).  
Private households' out-of-pocket payment on health as percentage of total health 
expenditure are the direct outlays of households, including gratuities and payments in-kind 
made to health practitioners and suppliers of pharmaceuticals, therapeutic appliances, and 
other goods and services, whose primary intent is to contribute to the restoration or to the 
enhancement of the health status of individuals or population groups. It includes household 
payments to public services, non-profit institutions or non-governmental organisations. It 
includes non-reimbursable cost sharing, deductibles, co-payments and fee-for service; 
excludes payments made by enterprises which deliver medical and paramedical benefits, 
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mandated by law or not, to their employees. It excludes payments for overseas 
treatment.”(104) 
The  international pharmaceutical manufacturer and supplier global market was worth 
USD1,105 bn in 2016 and is projected to reach  USD 1,485bn by 2021.(105) .  The global 
pharmaceutical market is expected to  reach  USD 1400bn in 2019 (106) and only 10 
countries in SSA (Algeria,  Egypt, Kenya, Ivory Coast, Libya, Morocco, Nigeria, South 
Africa, Sudan, and Tunisia) hold the promise of a market size about USD60bn in 2020.(107)   
The Top 10 corporations (Aspen, Adcock Ingram, Sanofi, Novartis, Pfizer, Cipla, Johnson 
and Johnson, Merck, Bayer and Roche) own 58% of the total pharmaceutical market share in 
South Africa; local companies make up 20.5% and global companies 37.5%. (106)  In 2015, 
the generics market in SA was R11.7bn (35.3% market value;49.4% volume of sales) and  
originator drugs made up  R16bn (48.2% market value; 29.7% volume of sales) (108).  The 
total South African pharmaceutical market was valued at  R44bn,  split between private 
R34.2bn (86.7%) and public R6.8bn (13.3%) sectors in 2015(108) and is forecasted to grow 
by  38% to reach R47bn in 2020(83).  In  contrast , the national  estimated drug expenditure 
in the public sector in 2000 was just R1.96bn(82).   
There is much less analysis, research and discussion generated around medical products 
expenditure in the public sector.   Information on medical products expenditure in the public 
sector is communicated in the Department of Health (DOH) Annual Reports and Medical 
Supplies Depot (MSD) Annual Reports reported by the provinces.  Public sector expenditure 
data is held by a small group of district, provincial and national health managers whose 
specific role dictates involvement.  It is not common for clinicians and managers at all levels 
to be involved and aware of budget and expenditure issues  in the public sector(109).  
Expenditure on medical products is not commonly analysed in the public sector within the 
DOH (82)and efficiency is not often a matter of public knowledge, thus more research is 
needed in this area.  Data from the private sector, referring to insured members of medical 
schemes, is available through statutory reporting to the CMS, industry reports from MCOs 
and analysis of claims data through ‘switching’ companies.  Much of the data on 
pharmaceutical and medical device spending is contained in industry reports specifically 
focussing on prices, market share, forecasts of growth in new markets and trends in revenue.  
Annual reports of Pharmaceutical manufacturers or wholesalers provide sales data such as 
non-prescription (‘over the counter’) drugs, generics, originator brands and specialised 
medicines.    
Additional sources of expenditure in medical products are through donations, such as the 
Fluconazole donation by  Pfizer to the NDoH,  and Conditional Grants for Tertiary services 
and HIV, from which about  60% is spent on ARVs(110).  Medical schemes fund medicines 
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through the risk pool or medical savings accounts and on a case by case basis through an ex 
gratia process.  Out of pocket expenditure for medical scheme beneficiaries  arise  out of co-
payments based on six major mechanisms: differences between the dispensing fees, use of  
non DSPs , out–of-formulary medicines  , reference price , maximum value  OTC  and set co-
payments.   Overall, in 2017, the differences between claimed and approved amounts was 
1.6% (58).   
Institutional arrangements for reimbursement in the medical schemes industry is complex:  
after registration with the newly formed SAHPRA regulator, pharmaceutical and medical 
device suppliers are expected to negotiate with MCOs to establish products within clinical 
protocols and formularies which correspond to medical schemes’ funding criteria.   This 
managed care gateway is based on rational drug use principles and evidence-based medical 
practice to manage demand in medical products (150).  However, the results of these 
measures often disadvantage users through OOP payments with implications for ATM.  User 
charges discourage use of chronic medications and affect vulnerable groups 
disproportionately (112). Influencing doctors by MCOs is an option to control expenditure but 
this usually has severe consequences to patients when quality of care is compromised in 
favour of aggressive cost savings (110, 111). Financing approaches and expenditure on 
medical products can have opposing effects on access.  Tighter controls of expenditure in 
medical products can lead to lower prices resulting in delays in accessing newer health 
technologies. Liberal expenditure may incur user charges and this also has an effect on 
access(113).  
The responses of the South African Medical Device Industry Association (SAMED) to the 
Healthcare market Inquiry (HMI) by the Competition Commission in 2016, summarizes major 
issues in medical devices expenditure.  SAMED emphasize that medical devices are not the 
most significant cost driver in healthcare, using CMS data (2013) which points to 7% of total 
industry expenditure on medical devices. This was supported by Discovery Health Medical 
Scheme Administrator, demonstrated R3.1bn (8%) in-hospital expenditure of total surgical 
spend on medical devices, majority of which were in-hospital.   SAMED suggest that surgical 
spend (which includes the use of medical devices) as a proportion of total hospital costs 
decreased from 2008 (21.5%) to 2013 (17.9%). A perspective offered by SAMED is that 
medical schemes set prices for the health technology industry and reject increases above 
inflation, disregarding effects of exchange rates on mostly (76%) imported goods(80).   
In the response to the HMI, the pharmaceutical task group (PTG) industry liaison body 
reports that medicines account for 1.1% of the 10.9% increase in medical claims expenditure 
according to Medscheme (85). Mediclinic and Netcare report about 9% of a hospitalised 
patient’s bill, is for medicines. From 2003 (22.3%), the expenditure on medicines for the 
private health industry decreased in 2013 (16%). This corroborates the report of the CMS 
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(2016/17) that private hospital (inpatient and theatre costs) (48%) and medical specialists 
(37%) are the top cost drivers in private healthcare(13).  
In the HMI, PTG acknowledged  a social commitment to supply medicines to the public 
sector but  listed many  challenges of conducting  business with the State, including: 
unaccounted logistics costs; lower prices on bulk purchase; marginal income from the State 
based on irregular tenders and unorthodox practices such as further price negotiations after 
closure of the tender process(85). Therefore pharmaceutical sales in the presence of robust 
price regulation and low purchasing efficiency in the public sector, is heavily dependent on 
the South African private sector, with less than 20% of the population (insured), bearing the 
cost of doing business.  
1.9 Conclusion 
Financing and  policy are the key mechanisms influencing access (42).  The role of policy 
and sustainable finance has been shown in frameworks for access to highlight supply side 
contributions to ATM(9).   ATM is most often dependent on access to healthcare   built on a 
broad national strategic vision and a plan to address pricing, quality, essential medicines, 
rational drug use, efficient selection and procurement processes and reorientation of the 
health system.  Health technologies are now an integral resource in the clinical care of 
patients and should be consistently available at the point-of-care.  When financing 
arrangements in the public are not sustainable or consistent across districts or provinces, the 
most vulnerable are disadvantaged by fewer alternatives to access care, lack of agency to 
demand quality and perpetuation of inequity across society.   
Alliance for Health Policy and Systems Research (WHO) 2012 set the international agenda 
for research in access to medicines based on limited contextual evidence and health 
systems understanding of ATM challenges particularly in LMICs. More research on health 
policy is needed as OOP spending was unsustainably high (50-90%).  The disparities in 
OOP spending between public and private sectors in these countries was 35% versus 66%. 
National expenditure on medicines represent 20-60% of the total health budget (114) .  
Access to medicines in LMICs is high on the policy and research agenda (47).  The WHO 
‘World Medicines Situation 2011’, stresses that data to assess ATM can inform a range of 
policy actions to ensure that the obligation of the State to provide healthcare to all citizens, is 
realised (61).  
The literature on medical products expenditure exists; however, it is not assimilated across 
sectors to present a high-level overview of medical products expenditure in South Africa.    
The results of this study will describe the policy, funding flows, expenditure trends and 
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analysis of medical products in South Africa. The objective of this work is to provide a 
descriptive overview of the major sources of funding for medical products in South Africa.  
This knowledge can be used to inform policy and health systems strengthening interventions 
to improve ATM for those whose need is greatest.  
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CHAPTER 2: METHODS  
 
2.1. Problem Statement  
Policy, finance and medical products are three building blocks at the forefront of service 
delivery and access to medicines.  Existing work focusses on policy analysis and critical 
reviews of the pharmaceutical and health technology policies (115,101,87,116)but few 
studies acknowledge the health systems impacts(100) . More health policy and systems 
research(HPSR) is needed to understand the complex interaction of building blocks which 
produce ATM as an outcome particularly in view of a new wave of reforms ushering in 
universal health coverage(117).   
Overall, health finance research covers broadly public, private and household health funding 
flows and is better described in the literature than medical products expenditure in SA. Few 
studies elaborate on the economic classification and component costs of healthcare such as 
hospitals, ambulatory care, medicines, medical devices and human resources yet this 
informs budgeting, impacts health inflation and influences access to healthcare(118). 
Without studying the effects of leadership and governance and financing on health outcomes 
(represented by ATM in this study) the three main intrinsic health goals (Health, 
responsiveness and fairness of financing) are neither understood nor operationalised(119).   
 
2.2. Study Rationale  
The study builds on policy analysis and critical reviews on pharmaceutical and medical 
devices sector reforms since the advent of the National Drug Plan in 1996, by shifting the 
research priority towards pharmaceutical system performance.  This work assesses progress 
made in SA through pharmaceutical reforms and advances the contextualisation of Access to 
medical products from a health systems perspective.    
Public, private and household level expenditure on medical products is analysed using 
publicly accessible and routinely collected information.  In this way, the study adds new and 
detailed insights into medical products expenditure in SA.  This knowledge is critical for 
efficient use of scarce healthcare resources and overall effectiveness of the health system.    
Importantly, this study presents an assessment of health system progress towards ATM 
using supply and demand side measures.  
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2.3. Study Aim 
The aim of this study is to analyse and describe policy reforms and funding flows of medical 
products in South Africa.  This will inform the development of new perspectives on access to 
medical products within the complexity of the health system.  
 
2.4. Research Objectives 
The specific research objectives were to: 
 Assess the South African regulatory framework for medical products using the Health 
Systems Assessment Approach (HSAA) which evaluates Pharmaceutical Policy, Law 
and Regulation. 
 Describe health expenditure on medical products in South Africa in public, private 
(supply-side) and household level (demand side) using available data. 
 Develop a health systems framework for understanding, and evaluating ‘Access to 
medical products’ in the South African context, which describes regulation, funding, 
product, distribution and information flows.  
 Analyse ‘Access to medical products’ in South Africa using four dimensions of access 
from supply and demand side perspectives.   
 
2.5 Selection of Study Design and Research Approach  
Descriptive and analytic methods were used in this study to understand the complexity of 
ATM in the SA health system, which is linked to the historical, political, sociodemographic 
and economic macro-context.    The exploratory approach facilitated deep insights into 
concepts, assumptions, behaviours and interactions of the key elements of the health 
system.     
This sequential exploratory mixed methods study was underpinned by data collection and 
data analysis processes.  Secondary data sources were used to conduct descriptive and 
regression analyses.  The quantitative analysis was done in two stages. In the first stage, 
descriptive statistics were produced from secondary administrative data such as Annual 
reports from CMS and DOH and survey data from Statistics South Africa (Stats SA).  The 
second stage of quantitative analysis involved building a multiple regression model using 
survey data from the Income and Expenditure Survey (IES) 2000 conducted by Stats SA.   
Household surveys can provide crucial information on how drug policies affect the individual, 
from the user’s perspective(120).  
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The results of the quantitative data analysis was used to formulate an interview plan.  Six key 
informant (KI) semi structured interviews were held; qualitative data was extracted from 
handwritten shorthand notes, captured, transcribed and analysed.  The Figure below is a 
schematic representation of a sequential dominant- status mixed methods design.  
 
 
Figure 3 : Sequential explanatory mixed methods design 
Source: Wu (121) 
 
2.6 Data Sources 
In this study primary and secondary data sources were used. For primary data collection, key 
informants (KIs) were identified based on relevant work or research experience in health 
technology and pharmaceutical systems, service delivery, policy, financing and willingness to 
participate in the study. Access to these individuals was negotiated through formal requests 
and informed consent for participation was obtained prior to the study.  Six telephonic KI 
interviews were held using the semi structured interview format. Prior to each interview, the 
participant was given an option of voice recording or note taking as a means to capture the 
data; one interview was recorded with permission from the interviewee.  The data was 
summarised and analysed in MS Excel spreadsheets, coded and categorised.  Semantic and 
latent themes were reviewed with a second researcher.  Emerging themes were summarised 
and tabulated.  The qualitative data informed the development of the schematic diagram for 
ATM in the SA health system.  
Secondary data formed the basis of the quantitative enquiry in this study. Private sector 
medical scheme expenditure data on medical products was extracted from Utilisation Annual 
Statutory Return (ASR) reports mandated by the Council for Medical Schemes (CMS).  
Additional medicines utilisation and expenditure in the private sector was obtained, with 
permission, from Mediscor (a Pharmacy benefit management company) industry analytic 
Stellenbosch University https://scholar.sun.ac.za
38 
 
reports, based on claims data of insured beneficiaries of selected medical schemes.  Public 
sector expenditure was extracted from provincial government Annual reports and National 
Treasury reports which are freely available in the public domain through the respective 
websites.  Expenditure data from these sources, were captured on MS Excel spreadsheets 
and descriptive statistical analyses were performed.   
The household expenditure analysis used Stats SA survey microdata accessed with 
permission from the  University of Cape Town  Data repository (Datafirst)(122).   The Stata 
v12 data files for each survey year were downloaded from the internet.  
The literature review was conducted in PubMed, Scientific Electronic Library Online 
(SCIELO), Cochrane, Popline and Google Scholar.   The institutional websites used were 
WHO, World Bank, MCC, HPCSA, SAPA, DOH, CMS, and Provincial government, Stats SA, 
HST and MSH. Annual reports, books,  research publications, internal communiques, 
meeting reports, conference summaries, presentations both published and unpublished  and 
other sources of grey literature were used.  Where necessary access was obtained from 
organisations.   
The policy assessment was based on the Health Systems Assessment Approach (HSAA) 
(2012 version) was developed by Health System 20/20, the Quality Assurance Project and 
Rational Pharmaceutical Management Plus/Management Sciences for Health.  The manual 
was first published in 2007 through United States Agency for International Development 
(USAID) funding.  It has been supported and implemented across 25 countries in Africa, 
Asia, Latin America and the Caribbean as well as USAID funded programs from 2006 to 
2012. The HSAA has been used to inform national strategic plans, PEPFAR partnership 
frameworks, grant applications, and numerous other health systems strengthening and 
programmatic activities.  In 2012, the HSAA manual was updated to reflect lessons learned 
through its application in more than 20 countries and thus validated as the appropriate tool 
for use in this study (123) .   
A number of data sources were used to assess ATM.  Routine data captured in the DHIS 
and reported in the District Health Barometer (DHB) (60) was used for public health services 
data.  Household data was obtained  from the General Household Survey(GHS) (2011-2016) 
microdata accessed through Datafirst(122).  
 
2.7 Data Entry and Storage  
Primary and secondary data collected in this study are subject to the Stellenbosch 
University’s copyright regulations. Safe keeping of the data is the responsibility of the 
researcher for the duration of the study. Data obtained in the study is stored on a password 
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protected laptop which is the property of the Centre for Health Systems Strengthening.  The 
data collected for the purposes of the study is subject to the provisions of the Protection of 
Personal Information Act (POPI).  
 
2.8 Data Analysis Plan  
MS Excel software (MS Office 360) was used to perform descriptive statistics on the 
expenditure data from secondary sources.  The descriptive analyses were subject to the 
limited availability of data in the public and private sector and therefore the time periods of 
analysis vary.   For the survey data, a multiple regression model was used to predict the 
effect of demographic variables on household spending on medical products in SA in IES 
2000. STATA 15.0 was used for quantitative analysis, licensed under Stellenbosch 
University.   
 
2.8.1 Data analysis for household expenditure on medical products  
The IES and Living Conditions Survey (LCS) are nationally representative sample of 
households and have been used to collect information on household expenditure to inform 
the Consumer Price Index (CPI).  The target population of the surveys consists of all private 
households or dwelling units (DU) in all nine provinces of South Africa and residents in 
workers’ hostels or quarters and is therefore only representative of non-institutionalised and 
non-military persons or households in South Africa(124).   
 
2.8.1.1 Survey methodology and data collection 
The IES 2000 payment and recall method was replaced by a combination of payment, 
acquisition and diary/recall methods for durable items and services in IES 2005 and 
LCS2008.  The aim of these changes was to improve utility and application of the data and to 
minimize biases in the methodology. Changes to the methods had a major effect on the 
results between 2000 and  2008(124) .  The debate around the quality and utility of data from 
these national surveys, analysed by Burger and Yu , Casale, Muller and Posel , and 
Wittenberg in Yu(125) , highlights methodological issues relevant to the interpretation of the 
data.  
The IES 2000 used the recall method to collect information on goods and services and 
identified according to the Standard Trade classification. From 2005, COICOP (Classification 
of Individual Consumption by Purpose) was introduced to classify expenditure items.  
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Households were asked Expenditure data from the surveys, which were annualised and 
inflation adjusted to ensure data comparability.  Significant differences were noted between 
the IES 2000 and 2005 results.  From 2008, a master sample design was employed across 
all household surveys which uses a two-stage, stratified design with probability–proportional-
to-size (PPS) sampling within strata.   
Although the methodology was changed between IES 2000 and LCS 2014, adjustments 
were made during the weighting process to offset any potential bias in change of sample 
design. Based on method integrity, household expenditure data in these surveys is 
comparable over years(124). The expenditure items captured in the LCS 2014 dataset could 
be mapped to the United Nations COICOP (5)codes and matched those of previous  
surveys.  Furthermore, the questionnaire specifically asked for annual estimates of 
household expenditure on medical products that were not covered by medical aid, insurance 
or any schemes that were OOP.   
 
2.8.1.2 Survey sample size 
The sample sizes  for periods relevant to this study were : IES 2000 (30 000 DUs); 2005 
(24000 DUs); LCS 2008 (31 473 DUs); 2010 (31 419 DUs) and 2014 (30818 DUs)(126).    
 
2.8.1.3 Study Variables  
There are common questions and variables used in the IES, GHS and LCS. The modules of 
the survey data were first merged using unique identifiers to create a dataset for the survey 
year containing all variables of interest.  The survey dataset was set up in STATA accounting 
for the two stage clustered survey design.   
The outcome (dependent) variables were defined in the survey dataset as “expPMDmedaid” 
and “expPMDnomedaid” to represent medical scheme membership status.  These variables 
represent household OOP expenditure on medical products. The expenditure items linked to 
these variables were mapped to COICOP codes.  The COICOP codes included in the 
outcome variables from the Health (061) category(5) and included : expenditure on medicine 
with prescription;  expenditure on medicine without prescription;  pharmacy dispensing fees;  
pharmacy service fees; other medical products and therapeutic appliances (see Glossary for 
details of these categories).  
This study reports on two main outcome variables the independent variables were 
descriptors of the demographic characteristics of the survey population.  The independent 
variables included in  the IES 2000 regression model were population group of head of 
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household (“Popgroup”) , province (“Province”), source of income (“incomesource”), 
settlement type (p0101q01) and number of persons in the household (“nopersons”) .  There 
were five categories of “Population group” variable (Black/African, Coloured, Indian/Asian, 
White and Other). The size of the household was a discrete number.  The variable “province” 
had 9 categories (WC, EC, NC, FS, KZN, NW, GP, MP and LP). The source of income 
variable had 9 main categories in 2000 and although 4 subcategories were added in 2014, 
they were easily mapped to the original IES 2000.  Only six of the income source categories 
with the highest frequencies were included in the analysis.  
 
2.8.2 Qualitative data analysis  
The qualitative data was transcribed and coded and thematic analysis was conducted.  The 
results of Phase one and two will be triangulated to validate the findings and to elicit 
emerging themes not introduced in the data collection and analysis phase.  Data  
triangulation  was done  combining  the  results of the quantitative(expenditure data) and 
qualitative(KI interviews)  data to identify agreement, partial agreement, silence , dissonance 
between findings from the different components of the study (127). 
 
2.9 Ethical Considerations  
The necessary authorisations and permissions were obtained to access documents routine 
financing and expenditure data. These were mainly in the form of industry reports of medical 
products expenditure data in the private sector.  Access to data is listed as a major limitation 
in this study and discussed in Chapter 5.  Anonymised routine data sources were used and 
therefore did not present any risks to patient confidentiality. There were no instances of 
patient identifiers in the data included in the analysis and therefore no risks to individual or 
organisations were presented.  The Ethical approval for this study was obtained under the 
number HREC Reference #: N17/09/089. 
This study was industry funded (Janssens Pharmaceutica) and mobilized a cross–faculty 
multidisciplinary research team towards improving policy and processes around financing 
and access to medical products. In the context of NHI, building capacity for policy and 
implementation whilst increasing public private partnership and collaboration, is a key 
competency.  No actual or potential conflicts of interest have been declared by the author, 
company or participating faculties of the University of Stellenbosch. The research paper will 
be made available in the public domain for the benefit of all sectors of the health system. 
This study will be submitted as a Master’s research project by the author.  
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CHAPTER 3: RESULTS 
 
3.1 Policy Summary and Analysis   
Using the HSAA framework for Pharmaceutical policy, laws and regulations, the basis for an 
efficient health sector with access to medical products was analysed.   The framework was 
not applied in its entirety; performance measurement criteria of the HSAA framework were 
omitted as this was not relevant to the study objectives.    The criteria for assessment were 
objectively based on legal and regulatory requirements in the process to make medical 
products accessible to users of the health system. This framework was used in the WHO –
SA NDOH collaboration in 2006 for the development of indicators to monitor country 
pharmaceutical situations and has been validated through its wide application (128).     
The key findings of the HSAA framework applied to the “Medicines, Vaccines and health 
technology” building block of the SA health system is shown in Figs 5 and 6 (below).  The 
aims of the NDP have been expressed in the regulatory landscape for ATM in South Africa 
since 1996 and the roadmap to achieve the instrumental health system goals (access, 
efficiency, effectiveness, quality, safety and equity) is in place. However, the NDP has not 
been revised since 1996 creating a void in some areas such as   strategies for supply and 
procurement; the role of the MSD, province and district, especially in view of the NHI’s 
objective of strategic purchasing; systems for pharmaceutical and medical device registration 
that consider capacity constraints, product life cycles, post marketing requirements (medical 
devices); provisions for licensing scenarios and conformity assessments.    
 Policies and guidelines for pharmaceutical registration and quality control in South Africa, 
are implemented and operational and can be extended to include medical devices. Until 
2017, medical devices were unregulated but the advent of SAHPRA through the enactment 
of the Amendments 2008 and 2015 has laid the foundation for implementation.   Systems for 
post marketing surveillance, pharmacovigilance, licensing, inspection and control have been 
established but need effective implementation.  Lastly, the HSAA framework reinforces the 
lack of adequate monitoring and evaluation (M&E) mechanisms to address progress towards 
ATM, performance of stakeholders, quality and financing.  
 
  
Stellenbosch University https://scholar.sun.ac.za
43 
 
Table 2 : HSAA Policy Summary Framework Part 1 
 
Existence of an National Medicines Plan or other government document that sets objectives and strategies for the 
pharmaceutical sector based on priority health problems  
The NDOH set up a committee in 1994 and with technical assistance from WHO and Action Programme on Essential 
Drugs, the first NDP was implemented in 1996.  The policy addresses inequitable access to essential drugs, quality of 
care, rising comparative drug prices, evidence of irrational drug use, losses through mismanagement, wastage, poor 
security, cost-ineffective procurement and logistics and undesirable industry incentive schemes (22).   
The Standard Treatment Guidelines and Essential Drugs List (later referred to as ‘Essential Medicines List’) series 
comprises :PHC (1996,1998,2006,2012,2015 editions); Paediatrics (1998,2006,2013,2017 editions ); Adult Hospital 
(1998,2006,2012,2015 editions).  Although WHO recommends more frequent updates, it is more feasible to conduct 
updates on a 5 yearly basis accounting for implementation time.  Most differences between SA and WHO EML are 
found in the Adult Hospital list(2012) although the PHC(2008) and Paediatric lists(2013) align (154).  
 
 
Regulatory framework - Medicines and Related Substances Control Act (1965) as amended (1997) (2008) (2015).   
Principles for selecting medicines , 
including donations 
Regulations  (R 1102 , 1210,524,657,1090,1256,766,714,264) 
Standard Treatment Guidelines and Essential Medicines List  
Establishment and function of Pharmacy and Therapeutics Committee Policy  
Section 21 Authorization  
Antimicrobial resistance Strategic framework 
HPCSA Guidelines for Good Practice in Healthcare Professions.   
HPCSA Code of conduct for Health Professionals  
Policy on Overservicing, Perverse incentives and related matters  
Strategies for Supply and Procurement  
 
Promotion of rational use of 
pharmaceuticals  
 
Economic and financing mechanisms PFMA(1999),Public service Act(1994) ; Promotion of   Administrative Justice 
Act(2000) ; Division of Revenue Act(2003) ; Broad Based Black Economic  
Empowerment Act(2003);  MFMA(2003) ; Appropriations Act ;Consumer 
Protection Act (2008); Patents Act (1978); Competition Act(1998); Copyright 
Act(1998)  
See Annexure for complete list  
Control of premises for Distribution  Pharmacy Act (1974) as amended 1997; 2000; 2015.                                             
Good Pharmacy Practice code , Good Manufacturing Practice , Good 
Wholesale Practice  
Role of Health professionals  Health Professions Act(1974)as amended 2003;2007 
Monitoring and Evaluation  Applicable policies, regulations and laws ; Norms and Standards regulation 
(National Health Act) 
Existence of a National Drug Regulating Authority responsible for the promulgation and enforcement of regulations  
The newly formed South African Health products Regulatory Authority (SAPHRA)   replaces the previous Medicines 
Control Council, created through the NDP and enacted in the 1997 Amendment of the Medicines Act.   SAHPRA    an 
organ of state, is subject to the Public Finance Management Act (PFMA) (1999), reports to the Minister of Health but 
holds final authority of all functions.  It has monetary autonomy, generating revenue from the service and function of 
the organization and only partly subsidized by the National Treasury.  Whereas the MCC mandate was as follows , 
SAPHRA is expected to take over these functions with extension to health technology :  Registration of medicines based 
on safety efficacy and quality ; Approval of clinical trials ;  Monitoring of safety ;  Response to signals ;  Licensing 
manufacturers, wholesalers and distributors ;  Ensuring compliance ; Provision of information to oversee  medicines, 
scheduled substances(155). 
 
 
Source: Author, Using HSAA framework(123) 
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Table 3: HSAA Policy Summary Framework Part 2 
Mechanisms exist for licensing, inspection and control 
Section 22C of the “Medicines” Act Amendment (2008 ad 2015) has extended licensing of medical devices.  Classification 
of Medical devices is critical to the licensing process.  SAPHRA is responsible for licensing, inspection and control of 
medicines and medical products. Two policies have been implemented by the MCC: License to Act as a Wholesaler of 
Medical Devices & IVDs; Guidelines for License to Manufacture, Import or Export.  Some of the supporting policies for 
these functions are : Hazardous Substances Act – electro medical and radiation devices;   Standards Act (2008) ; National 
Regulator for Compulsory Specifications Act [NRCS Act] ; Metrology Act ; SANAS: accredit inspection & certification 
bodies ; Foodstuffs, Cosmetics, Disinfectants Act.  The intent of the licensing process is to establish relevant quality 
assurance criteria for manufacture of medical devices in South Africa ; Identify requirements for importation of medium 
to high risk and high risk medical devices;  establish relevant distribution practices for distributors in South Africa ; 
establish a database of all medical devices imported and manufactured in South Africa by risk classification, by 
manufacturer or by distributor ; maintain details of Manufacturers, Distributors & respective Authorised 
Representatives(156) 
 
 
Existence of a system for pharmaceutical registration  
The registration process includes product efficacy, quality, safety and packaging instructions as contained in the 
regulations, however, there is some concern around the turnaround times for this process by the former MCC (157).  The 
registration   backlog in South Africa refers to a decision taken for all drugs on the EML, most of which are generics, to be 
offered a “fast track “process of registration. Multiple applications for the generic equivalent of a single drug were 
received. This provision has been omitted in the new Amendment Act(86). Efforts towards pooled procurement and 
regional standardization and Harmonization ,  under the African Medicine Registration  Harmonization  Initiative(AMRHI), 
offers increased  availability of quality controlled medical products and increased market size (158).   There main  
problems with registration in African countries are   registration costs and  commerce related  reasons  :  retention costs, 
GMP inspection fees and GMP inspection requirements resulting in withdrawal of such essential drugs as  allergy, anti-
infective, gastroenterology, HIV/AIDS, cardiovascular, metabolic disorders, pain management, psychiatry and 
gynaecology(159).   
 
Existence of a post-marketing surveillance system 
The policy response to a post marketing surveillance system, is the MCC Guideline  “Reporting Of Post-Marketing Adverse Drug 
Reactions To Human Medicinal Products In South Africa” which has been in place since 2003 and revised in 2015(160).  A 
National decentralized targeted spontaneous reporting (TSR) for specific drugs or patient groups was established to promote a 
multidisciplinary approach towards medical errors and systems failures.  active surveillance for adverse reactions  within 
existing cohort studies (two provincial systems) and cohort event monitoring (CEM) (two systems for patients receiving 
antiretroviral (ARV) medicines) were in place in 2012(161). The Draft National Strategic plan on HIV/AIDS, TB and STI 2017-
2022 seeks to implement the  national pregnancy exposure registry and birth defect surveillance programme at sentinel sites  
to assess safety profiles of commonly used drugs in pregnancy(162). 
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Existence of A Pharmacovigilance System 
The policy “Reporting of Post-Marketing Adverse Drug Reactions to Human Medicinal Products in South Africa” overseen 
by SAPHRA has been implemented since 2003 and relates to PV and ADR reporting.  Under reporting of ADRs is likely in 
South Africa as most health professionals, including pharmacists, do not have the capacity to identify or report ADRs.  In 
2012, it was agreed that data on ADRs were being collected by multiple programs and this warranted coordination at 
National level.  A national Pharmacovigilance (PV) Strategic plan was proposed.  Programs to report Immunization, 
HIV/TB and  specific clinical specialties (paediatric HIV and dermatology) were noted in 2012(160). Approximately 16 
percent of deaths in inpatient medical wards can be attributed to ADRs and an estimated 50 percent are preventable,  
impacting on  patient safety and quality of care and highlighting the need to capacitate HCWs in  management of   
ADRs(151,160,163) 
Source: Author, Using HSAA framework(123) 
3.2 Funding and Expenditure on Medical Products in South Africa 
3.2.1 National Health expenditure   
An overview of the National Total Health Expenditure (THE) provides an understanding of 
the principles, strategic priorities and politics of SA.  The  Global Health Observatory Data 
Repository reports SA national estimates of expenditure  on health showing  health budget 
allocation as a percentage of GDP  peaked between 2012 and 2014 (9%) and declined from 
2014 (8.7%; R145.7bn) to 2016 (8.5%; R168.4bn) as seen in Figure 4.  Public sector 
investment in health as a percentage of GDP, increased from 2005 (3.4%) to 2011(4.1 %), 
before reaching 4% in 2016.  Table 4 shows THE, private, public and OOP expenditure on 
health.  Overall, change in proportional spending between public and private sector is not 
overt;  incremental  domestic general  government spending on health(GGHE-D)  as a 
percentage of Current Health Expenditure(CHE) (53.6%) is met with  stabilising  domestic 
private sector health spending(PVT-D) (44%) in 2016  as opposed to  GGHE-D (41.1%) and 
PVT-D(57.6%) about a  decade ago in 2005.  In 2005 , public sector per capita health 
expenditure was USD  145.4( 29%) lower than the private sector( USD 203.8 per capita) 
however, this was reversed in 2015 ; private sector per capita health expenditure was USD 
207.2(17.8%) lower compared to the public sector (USD 252.1).  Although a steady decrease 
in OOP health spending as %CHE from 2005 (12.4%) to 2015(7.7%) was seen, OOP 
spending per capita, which is population based, showed more variation. 
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Figure 4: National Health Account Expenditure Estimates, South Africa 
Source: Author, based on Global Health Observatory Data Repository; Provincial Budgets and Expenditure review 
2005-2011 and 2010-2016 
 
3.2.2 Private sector (insured) expenditure on medical products  
3.2.2.1 Medicines Expenditure by professional category  
In 2016, as shown in Figure 5(Table 5) the total industry benefits paid in respect of medicines 
in the private sector was about R24bn.  Medicines amounting to R21bn (89%) was 
dispensed by pharmacists and R1.3bn (5%) by GPs, making up 94% percent of all medicines 
dispensed in the private sector.  Only 5% of medicine expenditure was incurred by medical 
specialists, support and allied and other health professionals (such as surgical specialities, 
radiology, pathology, anaesthetists, dental and medical technologists and dentists) combined    
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Figure 5 : Private sector (Insured) expenditure on medicines by Health Professional 
Source : Author, based on CMS data (123) 
Medicines expenditure incurred in “other health services” contributing 2% to the total spend 
includes blood transfusion services, ambulance, Foreign Service, travel clinics, clinical 
services, group practices and hospitals or clinics.   
3.2.2.2 Medical products Expenditure by Hospital type 
Figures 6 and 7 represent total medical scheme expenditure on medicines, consumables and 
equipment in private and provincial hospitals.  The term ‘private hospitals’ here encompasses 
day clinics and unattached operating theatres and Fee-for-service (FFS) hospitals(129), 
distinguished from  provincial(public sector) hospitals which are routinely used by members 
of low cost  medical scheme options.  There are vast differences in the nature of expenditure 
between these two types of hospitals. In 2010, private medical scheme members using 
provincial hospitals contributed 13.5% to total medical schemes’ industry expenditure on 
medical products, compared to 86.5% of expenditure incurred in private hospitals.  Table 6 
shows that over the period from 2011 to 2013, private hospitals consumed 98-99% of total 
industry expenditure on medical products.  
In 2013, private hospitals spent R3.7bn on medicines, R1.8bn on consumables and R632 
million on medicines as shown in Figure 6. Of the total spent on private hospitals, medicines 
constituted the highest proportional expenditure (60%), followed by consumables (30%) and 
equipment (10%), consistent from 2010 to 2013.   
Figure 7 and Table 6 shows private sector medical products expenditure in provincial 
hospitals.  In 2010, the medical schemes spent the largest proportion on consumables 
(75.7%, R 39.5m), followed by medicines (22.7%, R11.8m) and least on equipment (1.5%, 
R740 000).  This pattern changed drastically in 2011; the highest spend was on equipment, 
followed by medicines and lastly consumables.  By 2013 the pattern of private sector medical 
products expenditure in provincial hospitals was similar to that of private hospitals; medicines 
(48%, R9.6m); consumables (44%, R8.8m) and equipment (7%, R1.4m). The reporting 
format for private sector medical products expenditure changed in 2013, affecting line listing 
and economic classification of expenditure published in CMS Annual reports and limiting 
comparability of data.    
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Source: CMS Annual Reports 2010-2013 
 
 
 
 
 
 
Source: CMS Annual Reports 2010-2013 
 
3.2.2.3 Medicines expenditure by source of funds in private sector (Insured) 
A higher proportion of expenditure on medicines, as shown in the Figure 8(Table 7), was 
from pooled risk funds (ranging between 77%-80%) than from members’ medical saving 
Figure 6: Private sector (insured) expenditure on medical products in private hospitals 2010-2013 
Figure 7: Private sector (insured) expenditure on medical products in provincial (State) hospitals 2010-2103 
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accounts (ranging between 19%-23%) during the period 2008 to 2016.  In 8 years, medicines 
expenditure from risk funds doubled from R9bn (2008) to R18.4bn (2016); medicines 
expenditure from medical savings accounts, increased by a factor of 2.5 from 2008(R2.2bn) 
to 2016 (R5.6 bn).       
 
Figure 8 : Private sector (insured) expenditure on medicines by source of funds 2008-2016 
Source: CMS Annual Report 2008-2016 
 
 
3.2.2.4. Medicines expenditure by medical scheme benefit management (Mediscor)  
The pharmaceutical benefits of SA fee-for-service medical schemes are managed by 
Pharmaceutical Benefit Management (PBM) companies performing MCO functions.  Tables 
8 and 9 are based on data extracted from publicly available industry reports from Mediscor, a 
PBM company, accredited by the CMS, representing a number of medical schemes.  The 
dataset presented in these tables was based on approximately one million beneficiaries(58) .      
‘Prevalence’ refers to utilising beneficiaries as a percentage of total beneficiaries and 
‘Intensity’ refers to the number of items per utilising beneficiary.   
The average cost per beneficiary of the medical schemes sampled in this dataset, was 
R2617 per annum in 2016.  The average cost per item for 2016 was R150 and each utilising 
beneficiary (which in 2016 was 81% of the sample schemes population) was issued an 
average of 21.5 items for the year.   In the years 2014 to 2017, this trend is consistent.  Most 
commonly prescribed medicines by volume were acute(49%), PMB (29%)and OTC (14.4%) 
in 2016(58) .The top 10 therapeutic groups by volume are associated with acute infectious 
diseases (antibiotics, NSAIDs, antacids, analgesics  etc.)  
Mediscor beneficiary utilisation data shows that existing medicines constitute 98% of medical 
schemes’ expenditure and New Chemical Entities (NCEs) account for less than 2% of total 
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expenditure. NCEs are new chemicals submitted for registration for a new indication, or a 
previously known chemical in a drug which is newly recognised for its commercial value 
(152).  This pattern was also reflected in terms of the volume of medicines dispensed.  The 
average cost per item from 2014 to 2017 increased year-on year from R138 to the value of 
R165 although this was not the case for NCEs.  Average cost per item increased from R555 
(2014) over just three years to R906 (2017). The uptake and utilisation of NCEs was around 
2%, with the majority (80%) of beneficiaries using existing medicines.  The average number 
of NCEs dispensed to beneficiaries ranged between 2.5-3.3 items per annum and 21 items 
for existing medicines.  
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Table 4: National Health Financing Indicators South Africa 2005-2015 
Source: Global Health Observatory Data Repository; Provincial Budgets and Expenditure review 2005-2011 and 2010-2016, National Treasury, Provincial and local government 
database, Estimates of National Expenditure, Council for Medical Schemes, Road accident Fund and South African Reserve Bank  
Table 5: Private sector (insured) expenditure on medicines by Health Professional category 2008-2016 
Source: CMS Annual Report 2009-2016)  
Indicator 2005/6 2006/7 2007/8 2008/9 2009/10 2010/11 2011/12 2012/13 2013/14 2014/15 2015/16
Total Health Expenditure (THE) as %  GDP 8.7 8.4 8.5 8.7 8.9 8.7 8.9 9 9 8.7 8.5
Public Health Expenditure as  % GDP 3.4 3.4 3.4 3.7 3.7 4.1 4.1 4.4 4.4 4.3 4.2
Out of pocket as % of CHE 12.4        11.8        11.0        10.1        9.3          8.5          8.4          8.1          8.1          7.9          7.7          
GGHE-D as % of CHE 41.1 48.3 49.6 50.7 50.5 52.8 54.4 55 54.5 53.7 53.6
PVT-D as % CHE 57.6 50.2 48.6 46.9 46.7 44.2 43.1 43 43.5 43.7 44
GGHE-D  Expenditure per capita  USD  145.4 175 191.5 188.7 208.7 284.8 325.2 318.7 287.2 273.8 252.1
PVT-D Health Expenditure per capita USD  203.8      181.8      187.6      174.7      192.7      238.7      257.5      249.3      229.0      223.0      207.2      
Out of pocket per capita USD  43.7        42.7        42.6        37.8        38.2        45.9        50.2        47.1        42.5        40.3        36.2        
Public health expenditure per capita  ZAR 1722 1852 1953 2058 2134 2709 2915 2934 3021 3011 3011
Professional Category 2008 2009 2010 2011 2012 2013 2014 2015 2016
Pharmacists 10,007,914,000 11,108,357,000 12,742,782,000 14,775,873,896 13,816,244,350 16,699,706,683 18,290,506,792 19,778,776,612 21,225,169,130
General Practitioner 788,812,000 861,059,000 929,498,000 1,113,136,158 955,597,539 1,214,697,346 1,259,936,843 1,243,989,704 1,259,596,690
Medical Specialists 325,068,000 495,008,000 286,480,000 357,227,092 307,005,921 373,474,144 301,918,086 291,985,581 252,655,799
Support and Allied Health Professionals 23,265,000 25,468,000 15,650,000 24,612,570 20,940,334 74,010,728 89,601,874 105,147,679 138,508,155
Other Health Professionals 60,256,000 NC 65,766,000 69,170,480 61,028,538 279,920,474 314,764,696 496,516,268 642,819,192
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Table 6 : Private sector (Insured) expenditure on medical products by hospital type 2010-2013 
Source: CMS Annual Report (2010-2013) 
Table 7: Private sector (insured) expenditure on medicines by source of funds 2008-2016 
Source: CMS Annual Reports 2008-2016 
Table 8 : Private sector (Mediscor) data on medicines expenditure 2012-2017 
Source: Mediscor Medicines Review 2015-2017 
Source of funds 2008 2009 2010 2011 2012 2013 2014 2015 2016
Risk 9,048,304,000     10,757,169,000   11,202,641,000   11,919,079,163   12,941,658,248   14,994,887,131   16,194,876,467   17,252,731,129   18,386,208,103   
Savings 2,157,011,000     2,532,996,000     2,837,534,000     3,241,737,519     3,398,361,948     3,914,828,270     4,394,904,417     5,069,041,594     5,571,376,464     
Key expenditure indicators      (Annual) 2014 2015 2016 2017
Average cost per beneficiary 2526 2616 2617 NA
Average cost per item 140 150 150 165
Average # items per utilising beneficiary 22 21.9 21.5 21.8
Hospital type Item 2010 2011 2012 2013
Consumables 1,576,051,000          1,646,784,556 1,981,711,619 1,819,138,246         
Medicine 3,578,407,000          3,445,570,451 3,494,236,437 3,658,873,417         
Equipment 273,672,000 503,755,870 582,062,295 632,106,288            
Consumables 39,351,000 36,346,285 11,639,483 8,803,271 
Medicine 11,800,000 6,683,079 7,721,329 9,621,453 
Equipment 796,000,000 49,049,853 2,370,749 1,402,228 
Private Hospitals 
 Provincial(State) 
Hospital 
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Table 9 : Private sector (Mediscor) data on New Chemical Entities (NCE) expenditure 2014-2017 
 
Source: Mediscor Medicines Review 2015-2017 
  
New Existing New Existing New Existing New Existing 
% Expenditure 1.4 98.6 1.9 98.1 1.7 98.3 1.8 98.2
% Volume 0.4 99.6 0.4 99.6 0.4 99.6 0.3 99.7
Cost per item(ZAR) 555 138 737 148 604 148 906 165
% Prevalence 2 82 2.4 79.5 2.7 81 2.3 78.8
%Intensity 3.3 21.9 2.8 21.9 2.7 21.4 2.5 21.8
2014 2015 2016 2017
NCEs vs Existing medicines 
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3.2.3 Public sector expenditure on medical products  
3.2.3.1 Overall public sector medical products expenditure – 2013 
Medical supplies as a line item is comprised of medical devices and diagnostic equipment 
under R5000.  Figure 9 and Table 11 presents a ‘snapshot’ of the provincial breakdown of 
operational budgets across SA in 2013.  In this year, Mpumalanga (MP), KwaZulu Natal 
(KZN) and Gauteng Province (GP) respectively, recorded the highest proportional 
expenditures for medicines; the mean(SD)  medicines expenditure  across all provinces  in 
2013 was  7.3%(1.66)of the operational.  The median medicines expenditure was 6.9% in 
2013.  
 
Figure 9 : Public sector operational health expenditure by Province, 2013 
Source: Author, based on National Treasury Report 2013 
 
North West (NW) and Western Cape (WC) provinces held joint first position for medical 
supplies expenditure followed by GP and KZN respectively. The mean (SD) for medical 
supplies expenditure was 4.3% (1.65) of the operational budget with a median of 4.1%.  
Although there were differences between the provinces, overall, there was consistency in the 
public sector around expenditure on medical products. Medical products in the public sector 
EC LP GP WC FS KZN MP NC NW
Payments for Capital assets 6,3 2,3 3 5,3 6,8 6,3 6,9 14,8 12,4
Property payments 5,6 1,3 5,1 4,5 0,4 2,7 1,4 3,3 4
Inventory : Agency and
support/outsourced services
1,4 3,9 1,1 2,5 1,3 3,2 0,9 2,2 2,2
Inventory : Laboratory costs 3,7 2,4 2,2 3,3 3,3 2 2,8 2,5 2,7
Inventory : Medicines 6,4 6,9 8,1 5,6 7,5 8,5 10,6 5,7 5,6
Inventory : Medical Supplies 3,1 1,4 5,9 6,4 4 4,5 4,1 3,6 6,4
Compensation of employees 62,8 71,4 62,4 58 66,2 63,2 61,9 52,5 57,9
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consumed a median of 6% of the goods and services budgets in the provincial Departments 
of Health.  
3.2.3.2 Public sector expenditure on medicines by province 
Figure 10 and Table 12 shows expenditure on medicines in each province from 2011 to 
2016. Missing data entries for LP, NC and MP were noted and therefore any summary drawn 
from this data is to be interpreted with caution. The median change in expenditure from 2011 
to 2016 was 5.3%, however, the outlier was a 16.6% increase between 2013 and 2014. KZN 
(R3.5bn; 29%) and GP (R3.1bn; 25%) incurred the highest expenditure on medicines in 
2016. These two provinces alone accounted for 54 % of national expenditure (R12.3bn) on 
medicines; WC and EC combined constituted 22% of the total spend.   In 2015, the national 
expenditure on medicines in the private sector was R10.9bn.  The median increase year on 
year was 12% from 2011 to 2016.  Incremental investment in medicines   is noted in all 
provinces over the last 6 years. KZN, GP and EC respectively consistently account for the 
top three provincial   expenditure on medicines, while NC, LP and NW/FS represent the 
lowest expenditure on medicines.  In 2011, the national expenditure on medicines was 
R6.3bn and in 5 years, this doubled to R12.3bn in 2016, despite the absence of expenditure 
data from the MP province.  
Figure 10 : Public sector expenditure on medicines by Province 2011-2016 
Source: Provincial Annual Reports 2011- 2016 
3.2.3.3 Public sector proportional expenditure on medical supplies 
Expenditure on medical supplies per province from 2011 to 2016 is shown in Figure 11 and 
Table 13. Missing data entries for MP were noted and therefore any summary drawn from 
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this data should be interpreted with caution.  The total expenditure on medical supplies in the 
public sector in 2016 was R6.7bn.    The three provinces with highest expenditure were GP 
(R2bn), KZN (R1.5bn) and WC (R1.3bn) respectively, constitute 73 %( R4.9bn) of the total 
national expenditure on medical supplies in 2016. The top three provinces’ expenditure trend 
was consistent in the review period.  GP and KZN alone account for 53% (R3.5bn) of total 
national spending on medical supplies. The median change in the expenditure year-on-year 
was 1% however, in 2013, there was a reduction in expenditure by 13%, which had a knock-
on effect in 2014, where a 12% increase was seen. The lowest expenditure was in NC 
(R158m), consistent with lower levels in prior years; R110m (2013), R124m (2014) and 
R117m (2015).   In 2011, the national expenditure on medical supplies was R6.3bn and in 
2016 the expenditure was R6.7bn, considering the absence of data for MP province.   
 
 
 
 
Figure 11 : Public sector expenditure on medical supplies by Province 2011-2016 
Source: Provincial Annual Reports 2011- 2016 
 
The proportional expenditure across the provinces shows that GP (30%), KZN (23%), and 
WC (20%) dominate the spending on medical supplies.  As seen with medicines expenditure, 
NW and FS (5%), LP (4%), NC (2%) shared the lowest proportions of the total national 
spending on medical supplies.  
3.2.3.4 Expenditure on medical products across all provinces  
Public sector expenditure on medicines and medical supplies across all provinces from 2011 
to 2016 is seen in Figure 12(Table 10).  This data was sourced from National Treasury 
Provincial Reports and therefore differs slightly from data presented in Figures 10 and 11 
above (Public sector medicines and medical supplies) and Tables12 and 13 below.  
Stellenbosch University https://scholar.sun.ac.za
57 
 
Furthermore, mid- term estimates and not actuals in the period from 2014 to 2016 were 
included in Figure 12(Table 10).  The average proportional expenditure on medicines (63%) 
and medical supplies (37%) from 2010 to 2016.   
 
Figure 12: Public sector expenditure on medical products, All Provinces 2010-2016 
Source: National Treasury Provincial Budget Review 2016 
 
Table 10: Public sector expenditure on medical products, All Provinces 2010-2016 
 
Source: National Treasury, Provincial Budget Review, 2013 
 
 
 
 
  
2010 2011 2012 2013 2014 2015 2016
Inventory : Medical Supplies 4 999 4 926 5 402 5 707 6 023 6 747 7 235
Inventory : Medicines 7 264 7 689 8 991 9 877 10 774 12 046 13 207
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Table 11 : Public Sector operational expenditure on medical products by Province 2013 
Source: National Treasury, Provincial Budget Review, 2013 
 
Table 12 : Public sector expenditure on medicines by Province 2011-2016 
Source: Author, based on Provincial Annual Reports, All Provinces, 2011-2016      *Not reported                  
 
Table 13 : Public sector expenditure on medical supplies by Province 2011-2016 
Source: Author, based on Provincial Annual Reports, All Provinces, 2011-2016      *Not reported                  
 
3.2.4. Household expenditure on medical products in South Africa  
The results of the study of household survey data to determine household expenditure on 
medical products was based on survey data from the IES 2005, 2010 and LCS 2008 and 
2014. In the IES 2005, 2010 and LCS 2014, it was possible to examine disaggregated 
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expenditure on ‘pharmaceutical’, ‘therapeutic appliances and equipment’ and ‘other medical 
products’ categories, however, this classification was not consistent in the LCS 2008. 
In the four surveys from 2005 to 2014, SA households spent more on medical products than 
outpatient health services. The median household expenditure   on medical products, which 
included pharmaceuticals , appliances and equipment was  0.7% of the total household 
expenditure on health  , which in real terms was an average annualized  R542(SD 193.4). In 
contrast, during the same period, the median expenditure on outpatient health services was 
0.6% of total household spending on health (R493; SD 183.3) as seen in Table 14.     
Figure 13 shows average SA household expenditure by expenditure groups   demonstrating 
that pharmaceuticals constitute a larger proportion of household expenditure than therapeutic 
appliances and equipment and other medical products over the period 2005 to 2014.   
Figure 13: Household OOP expenditure on medical products by expenditure group 
Source: IES2005, IES 2010 and LCS2014 
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3.2.4.1 Household expenditure on medical products by sex of Household head 
Median spending in male headed households was 0.65% as compared to 0.7% for female 
headed households over the survey periods from 2005 to 2014 as shown in Figure 14(Table 
14).  Changes to the questionnaire in 2008 impacted the data collected on medical products 
expenditure; female headed households spent more (1.2%) on medical products than male 
headed households (0.9%) in that year. Figure 14 show females headed households spent 
less on medical products, in real terms, across all survey years.  The average spent by 
female headed households was R404.8 (SD165) and that of males was R622 (SD216).  
 
 
Figure 14 : Household OOP expenditure on medical products by sex of Household head 
Source: IES 2005, LCS 2008, IES 2010 and LCS2014 
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Figure 15: Household OOP expenditure on medical products, by Sex of HH head, real values(R) 
Source: IES 2005, LCS 2008, IES 2010 and LCS2014 
 
3.2.4.2. Household expenditure on medical products by settlement type  
The IES 2005 survey distinguishes only two settlement types namely urban and rural; this 
was changed in the LCS 2008 to urban formal (UF), urban informal (UI), rural formal (RF) 
and traditional areas. Urban households allocated an average of 0.8% of household 
expenditure on medical products over the period 2005-2014 in the four surveys, compared to 
0.7% in rural households as seen in Figure 16(Table 15). Both urban and rural households 
spent more on medical products than outpatient services. Urban informal households spent 
66% less than urban formal households on medical products; rural formal households spent 
41% less than urban formal. The average urban household spent R940 per year over the 
survey periods compared to rural households (R585) on medical products.  
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Figure 16 : Household OOP expenditure on medical products, by Settlement type 
Source: IES 2005, LCS 2008, IES 2010 and LCS2014 
 
3.2.4.3 Household expenditure on medical products by province   
The average household across all provinces spent 0.6% of total household expenditure on 
medical products   in the survey periods from 2005 to 2014, as shown in Figure 17(Table 18).  
In 2005, households committed a larger proportion of household expenditure to outpatient 
services than medical products, except in the FS province where medical products formed 
1% and outpatient services 0.9%. This trend was unchanged in 2014 with a higher 
proportional spending on outpatient services.  The average expenditure in real terms from 
2005 to 2014 was R536 (SD 193) as shown in Figure 17.  The provinces with the highest 
household expenditure on medical products in 2005 were FS (0.9%), NW and EC (0.7%), 
WC/NC/KZN/GP (0.6%).  Although the average household expenditure on medical products 
across SA had decreased between 2005 and 2014, the highest household expenditure was 
in FS (0.8%), WC/NC (0.5%), and KZN (0.4%) in 2014. 
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Figure 17 : Household OOP expenditure on medical products by Province 
Source: IES 2005, LCS 2008, IES 2010 and LCS2014 
3.2.4.4 Household expenditure on medical products by expenditure deciles 
From 2005 to 2014, household OOP expenditure on outpatient services (0.5%) was lower 
than that of medical products (0.7%).   Changes in average household spending on medical 
products, in real terms, were not linear from 2005 (R350), 2008(R392), 2010(R697) and 
2014 (R387), as shown in Table 17. In 2005, the average spending on medical products was 
R350 (median R136) ranging between the minimum R41 in the lowest decile to the maximum 
R1797 in the highest expenditure decile.  The average spending on medical products across 
all expenditure deciles in 2014 was R387 (median R 187), however, this varied greatly 
between the lowest decile (R46) and highest decile (R1668).  
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Figure 18 : Household OOP expenditure on medical products by Lowest Expenditure deciles 
Source: IES 2005  
Figure 19 : Household OOP expenditure on medical products by Highest Expenditure deciles 
Source: IES 2005 
 
Figures 18 and 19 shows the unequal distribution of expenditure on medical products 
between the lowest and highest five expenditure deciles in 2005. The average spent on 
medical products in the lowest 5 deciles in 2005 was R156 (SD 100) compared with the 
average spent in the upper five deciles which was R916 (SD 826).  These values were 
widely dispersed around the mean.  Expenditure on outpatient services was similar to that of 
medical products except in the two highest expenditure deciles, (i.e. expenditure deciles 9 
and 10) where outpatient services spending steeply increased, widening the gap between 
services and medical products expenditure.  Between decile 9 and 10, expenditure on 
services increases relative to that of medical products.  A similar widening of the gap 
between expenditure on services and medical products at household level is also seen 
between the deciles 4 and 5.    
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3.2.4.5 Household expenditure on medical products by income deciles  
In 2005, both lower and upper income deciles spent 0.6% of total expenditure on ambulatory 
care (out of hospital) spending on medical products, as seen in the Figure 20(Table 16).  In 
2005, a higher proportion of ambulatory care expenditure was spent on outpatient care.  The 
lower 5 income deciles spent an annual average of R181 (SD 95) in the survey periods from 
2005 to 2014. The upper 5 income deciles spent an annual average of R866 (SD 736) 
between 2005 and 2014 although there was wide variation around the mean.   
 
 
Figure 20 : Household OOP expenditure on medical products by Income deciles 
Source:  IES 2010 
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Table 14 : Household OOP expenditure on medical products by Sex of Household head 
Table 15:  Household OOP expenditure on medical products by Settlement type 
Table 16 : Household OOP expenditure on medical products by Income decile 
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Table 17 : Household OOP expenditure on medical products by Expenditure deciles 
Table 18 : Household OOP expenditure on medical products by Province 
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3.2.4.6 Summary of Multiple Regression Analysis 
A multiple regression analysis was conducted to predict the effect of demographic variables 
on household OOP expenditure on medical products. Household survey data was 
comparable only from 2005 -2014 and excluded any prior surveys therefore, the IES2000 
was used in this inferential statistical analysis, to understand the trajectory of household 
spending on medical products prior to 2005 (124,125).    In total 26 182 observations were 
recorded across 18 strata and 2956 PSUs in the IES2000 household survey.  Table 19 
summarises the descriptive statistics for OOP medical products expenditure in households 
based on membership status of medical aid schemes.  
The sample was composed of majority Black/African households (75%), White (14%), 
Coloured (8.3%) and Indian/Asian (2.5%).  More urban households were sampled (64%) as 
compared to rural (36%).  Most families consisted of 1-5 members (78%). Twenty percent of 
families in the sample had between 6-10 members and only 2% had more than 10 members 
per household. The main income sources were regular income (69%), salaries and wages 
(21.4%), regular receipts from grants and funds (8.27%), nett profit from business (3.14%) 
and Alimony (1.97%).  
The highest average annual spending in 2000 was seen in the White population group 
(R611.8 per year in medical scheme members and R224.3 in non-medical scheme 
members) followed by Indians/Asians (R146 in members and R85.3 in non-members). 
Black/African households spent the least on medical products regardless of membership 
status (around R21 per annum).  Across all population groups, households with non-
members incurred less OOP expenditure on medical products than members of medical 
schemes   
Households in GP and WC were the highest spenders in both public and private sectors. 
Households in LP, NW and EC incurred the lowest OOP expenditure on medical products. 
Across all provinces, households without medical aid or insurance incurred less OOP 
expenditure on medical products compared to members of medical schemes. Uninsured 
households in LP reported an average annual expenditure of R7.8 on medical products, 
while GP insured households in GP spent R178.9 per annum.  
Insured households in urban areas spent more per annum (R956.8) on average than insured 
rural households (R439) and this urban-rural pattern was repeated in the uninsured 
households.  
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Table 19: Descriptive Statistics - Income and Expenditure Survey 2000 
n=26 182 
 
% Mean SD Mean  SD 
  
ZAR 
 
ZAR 
 
Population group of HH head  
 
Private  
 
Public  
 
Black/African  75 20.5 270.9 21.1 122.8 
Coloured 8.3 40.1 302.8 57.4 352.5 
Indian/Asian 2.5 146.6 576.3 85.3 280.4 
White 14 611.8 1327.6 224.3 682.9 
Other  0.25 218.7 529.5 47.4 97.2 
Province  
     
WC 9.5 175.8 824.4 109.9 49.2 
EC 14.4 54.9 473.2 24.7 204.7 
NC 4.6 98.1 1241.5 42.6 417.4 
FS 7.8 124 892.7 60.2 739.2 
KZN 18.9 89.1 635.1 47.1 254.8 
NW 10.1 47.4 468.2 30.1 271.2 
GP 13 178.9 804.4 80.5 362.2 
MP 9.1 71.9 520.1 40.2 291.9 
LP 12.8 27.3 389.3 7.8 72.5 
Settlement type  
     
Urban  64 956.8 1742 396.9 752.2 
Rural  36 439.1 706.9 234.9 791.6 
Income Sources  
     
Salaries and Wages  21.46 1076.8 2268.1 435.3 879.8 
Net Profit  3.14 1343.2 2736.4 456.4 830.4 
Interest received  0.14 345.9 68 283.4 294.2 
Regular receipts  8.09 1292.9 1348.7 1224.6 1371.1 
Alimony 1.97 448.4 644 90.1 102.3 
Regular allowances  1.4 1882 3416.8 78.4 126.9 
Total regular income  63.62 877.4 1599.9 321.8 615.3 
Household size 
     
1 
 
935.9 1738.6 396 767.4 
2 
 
588.2 919.7 101 113.6 
3 
 
488.5 251.4 74.7 30 
4 
     
5 
 
146 153.8 69 80.9 
 
Source: Author, IES 2000 using Stata v15 (STATACORP) 
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The regression models for OOP medical products expenditure in households with and 
without medical aid based on the IES 2000, is given in Appendix C and D respectively. The 
regression model was able to predict only 7.9% of the variability seen in expenditure on 
medical products in insured households.   
Province and household size were not predictors of average household OOP expenditure on 
medical products. The average annual household expenditure on medical products for 
insured households increases on average by R109 for Indians/Asian (p=0.005) and R590 for 
White (p<0.000) population groups, as compared to Black/African population group, holding 
all other variables constant.  The average OOP expenditure on medical products in insured 
households decreases by R31 for rural settlement type (p=0.002) as compared to urban 
settlement type, holding all other variables constant. The average household expenditure on 
medical products by medical scheme members decreases by R322 where the income source 
is subsistence farming (p=0.032) and by R151 where royalties are the income source 
(p=0.013) holding all other variables constant.  
In households with non-members of medical schemes, the regression model was able to 
predict on 6.8% of the variability seen in OOP expenditure on medical products.  In the NC 
(p=0.004) and LP (p=0.041) in uninsured households, decreases in medical products 
expenditure by R50 and R38 respectively, as compared to the Western Cape is seen, 
adjusting and holding constant, all  other variables in the model. Household size, settlement 
type   and income source were not predictors of average OOP expenditure on medical 
products in uninsured households.  The average household OOP expenditure on medical 
products in uninsured households increases by R56 in Indians/Asian (p=0.001) population 
group and by R187 in White (p<0.001) population groups, as compared to Black African 
population group, holding all other variables constant.    
 
3.3 Summary of Qualitative Data  
3.3.1 Overview of interviews  
The six key informant interviews yielded qualitative data that confirmed assumptions and 
publicly held views of ATM in SA.  Interestingly, the information highlighted concerns and 
challenges of practical significance that was not well documented in the prevailing literature.  
The KIs were adept at relating their professional activities within the ATM context and 
articulating their roles and contribution to the overall health system ATM goals.  Each 
interviewee was well placed within their professional remit, to offer in-depth insights into 
funding, policy, governance, HR, health technology, supply and procurement and health 
information management (i.e. health system building blocks).  Two perspectives of ATM 
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emerged – the strategic and the operational levels.  The differences between the public and 
private sectors are highlighted in the themes.  
Three KIs were well versed in ATM research, analytics and consultancy.  Their interviews 
confirmed the major themes elicited in the literature review on health technology, policy, 
finance and ATM. They were executive level decision makers, industry and opinion leaders.  
The interview covered the urgent, complex, and controversial issues of medical products 
policy, funding and access.   
Three interviewees were professionally engaged at an operational level within the health 
system and offered unique views, many of which were undocumented, of the challenges and 
opportunities in human resources and service delivery.  These KIs were employed in critical 
roles at or near the frontline of service delivery, a vantage point from which knowledge 
translation and policy implementation could be assessed. Each KI related the complexity of 
operations enabling the realisation of ATM, by adopting pragmatic approaches rooted in 
management, public administration and policies to exploit resources optimally.    
There was coherence around many of the themes elicited through the KI interviews and the 
critical literature review conducted. The KIs were able to provide experiences, empirical and 
anecdotal evidence of the policy process, regulation and implementation. The preliminary 
quantitative results could be ‘verified’ as these impressions were intuitively known and well 
accepted in the industry.  The findings of the qualitative interviews were coherent with the 
themes identified in the policy and health systems ATM literature. Additionally, the 
quantitative data reinforced the emergent knowledge with respect to medical products 
expenditure (from CMS and DOH reports) and household survey data.     
The NDP was accepted as a strategic document that spearheaded reforms in ATM. All 
agreed that there were many success of the NDP, but were aware of the delays and failures 
of implementation.  KIs agreed that regulation was necessary for medical products, but there 
was some dissonance in what should be prioritised.  The implementation of the NHI received 
mixed responses with most KIs identifying the opportunity for further reform and bemoaning 
the lack of clarity around the details of implementation.  There was consensus that NHI has 
the potential to overhaul the current health system but concerns abound about capacity of 
the regulator, health system functions (financing and service delivery), human resources and 
information system.  
The operational level issues raised were also confirmatory of the literature. Supply chain 
management in the public sector was the dominant theme.  KIs had detailed knowledge of 
process bottlenecks and resource constraints and shared many management -driven 
solutions and best practices within their contexts.  The KIs were perceived as experts in their 
respective fields but were unable to execute on improvement initiatives based of lack of 
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management, resource and time constraints. Table 20 below summarises the key themes 
highlighted in the interviews.  
The public and private sector themes are given below in Tables 21 and 22. 
Table 20: Emerging themes from Key informant interviews 
   Source: Author, based on key informant interviews 
Industry/Sector Content Area Themes 
Public Sector District and Provincial 
Management 
Financing, procurement, clinical governance, rational use, reporting , MSD capacity, training HR, SCM, 
stock outs.  Policy, procurement, clinical governance , rational use, finance, reporting process, Sub 
district  capacity to manage procurement and SCM 
Private Sector Retail pharmacy Generic utilisation, Generic uptake as pharmacy performance criteria. MCO incentives for  retail 
pharmacies(Designated Service Providers) , OOP spending in private , Top 5 generic and originators in 
private, Consult in public buy in private, locals vs foreign nationals, average  cost chronic self funding  
Private Sector Provider Management Managed care funding  ,  Registration delays,SEP, inhibitory regulation, regulatory authority capacity 
constraint ,formulary limitations  , providers input costs , co-payments , government capacity, NHI
Academic Research Regulation , Policy  SEP,price setting, dispensing fee, NHI,access to PMD,clinical governance ,capacity of 
SAHPRA,public financing of medicines and devices, MSD capacity, private financing ,managed care , 
rational drug use , pharmacy practice 
Private Sector Health Technology Assessment Device registration, licencing ,classification of medical devices, capacity of SAHPRA, product registration, 
price controls, cost effectiveness , public sector procurement, managed care funding , HTA, NHI
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Table 21: Summary of Public Sector themes 
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Table 22: Summary of Private Sector themes 
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3.4 Health Systems approach to Access to medical products in South Africa 
The health systems approach involves an integrated understanding of the interaction of the 
building blocks in realising the goal of access to medicines.  Figure 21 is based on a  
focussed literature review of supply chain, logistics, procurement and regulatory frameworks 
(76, 66, 117, 9) for medical products, combined with qualitative data from interviews.   
3.4.1 Medicines, Vaccines and Technology Product flow 
Medical product suppliers use national wholesalers, local manufacturers and distributions 
networks, which are regulated by SAHPRA.  Medical products are procured in the public 
sector predominantly on national or provincial tenders but also on a quotation basis.  Medical 
Supplies Depot (MSD) procure, supply and deliver medical products to health facilities 
however, there are serious efficiency concerns resulting in direct engagement with 
wholesalers and distributors.  Product flows in the private sector occurs directly to providers 
(wholesalers) and provider organisations (retailers) however, medical schemes acting 
through MCOs exert considerable influence on reimbursement thereby impacting ATM.   
Individuals access medical products through direct OOP payments at private retail 
pharmacies.   
3.4.2 Health Financing 
In the public sector, health services are funded by National Treasury allocations to NDOH 
and transferred to provinces using the Provincial Equitable Share (PES) formula and 
conditional grants.  Large donations in the public sector, such as the South African 2000 
Diflucan partnership, is a vehicle for funding of medical products in developing countries. 
Provinces allocate budgets to District health services which are responsible for PHC. (130) 
while larger institutions like, central, regional, specialised hospitals have their own 
operational budgets.  In the private sector, medical schemes reimburse services provided to 
members by providers (dispensing clinicians) or retail pharmacies in accordance with benefit 
design and managed care protocols.  OOP in SA occur when consumers self-fund their 
health expenditure or when scheme members incur co-payments, deductibles and balance 
billing.    
3.4.3 Health information and Service Delivery 
Data is generated from service delivery interfaces at clinics, hospitals (district or provincial) in 
the public sector.  Although the process of digitization is underway, paper based routine 
monthly data is captured and validated as it ascends from clinic level through the DHIS to 
District, Provincial and National DOH. At the point of service in the private sector, claims, 
reimbursement and logistical data is generated, for MCOs through switching companies.  
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The medical schemes industry regulator (CMS) reports consolidated industry results based 
on statutory data reporting by medical schemes.  
3.4.4. Human Resources for Health 
The International Pharmacy Federation (FIP)(131) showed in the Global Workforce Report in 
2012 that an HR focus in Supply chain management (SCM) is needed to address the link 
between a lack of pharmacy personnel and inequalities in access to medicines. Strong 
supply chains are essential for positive health outcomes and require a competent, 
recognized and supported supply chain workforce with significant technical and managerial 
capacity. This requires systematic approaches to plan, finance, develop, support, and retain 
the national workforce. In the SA context, the nurse driven PHC services in the public sector 
requires that nurses, in addition to their primary clinical roles, dispense medication and 
maintain responsibility for stock flow management.  A cadre of ‘Pharmacy assistants’ were 
created to address the shortage of registered pharmacists in the country(132). In 2014, there 
were 13 364 registered pharmacists in SA and 4516 employed in the private sector(132).  In 
the private sector, there are fewer dispensing doctors, both GP and specialists.  With the 
advent of oral oncology drugs and IV treatments, medical oncologists have become, in effect, 
dispensing doctors as they claim service fees(58). 
3.4.5 Governance and Leadership 
NDoH provides stewardship in the health system however the executing authority in the SA 
public health system lies with the Provincial health department.  NDoH provides leadership, 
policy development and regulatory oversight across the health sector through various 
agencies established in law.  SAHPRA is the regulatory body, established in terms of the 
MRSA (1965) and Amendments (2008 and 2015) , as a public entity outside the NDoH  
responsible for the  accreditation, licensing, quality, pricing, research practice, evaluation  of 
medical products and medical devices.  The CMS is the statutory regulator of the medical 
schemes industry providing oversight to not-for-profit medical schemes and their contracted 
MCOs.  Medical schemes play the role of Funders of private healthcare for the insured while 
the role of MCOs is governance and clinical risk mitigation.  HPCSA, Nursing and Pharmacy 
Councils regulate health professionals’ and pharmacists’ practice.   
Figure 21 below demonstrates the interaction of the health system building blocks in the 
South African context in relation to ATM.   
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Figure 21: Health systems diagram for ATM in South Africa 
 
Source: Author  
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3.5 Assessing Access to medical products in South Africa  
3.5.1 Assessing supply-side determinants of ATM  
A dashboard of DHIS service indicators was compiled to assess supply side determinants of 
ATM. These indicators served as proxy measures of accessibility, availability, acceptability 
and affordability.  Based on the DHIS data source, these results are more relevant to ATM in 
the public sector.  
The PHC utilisation rate shows that the average public sector client visits the PHC facility 
more than once per year.  From 2000 to 2015, the national PHC utilisation rate increased 
from 1.9 to 2.3 visits per year, which infers improved accessibility of services (153).  
Availability of medical products at PHC level was assessed by the indicator ‘Tracer item 
stock out rate’ as seen in Table 23.  The indicator is defined as the proportion of all fixed 
clinics, Community Health Centre (CHC) or Community Day Clinics (CDC) with a stock out of 
any tracer drug. Stock out rates increased between 2011 (10.5%) to 2014 (23.6%) and 
decreased in 2015 (22.6%). The second indicator refers specifically to HIV/AIDS and TB 
drugs, in recognition of the importance of treatment adherence, patient compliance and drug 
availability impacting patient health outcomes. The three consecutive years show an 
unacceptably high percentage of stock outs in these essential drugs. 
“Acceptability “was assessed using the GHS indicator, “Percentage of users of public health 
services very satisfied with the service they receive”. This measure of Acceptability was used 
in both demand and supply side assessments.  The GHS data showed that average 
satisfaction experienced in the private sector was higher than in the public sector. Table 23 
shows that from 2009 to 2015, the proportion of users satisfied with public health facilities 
has increased from 54.5% to 57.6%.   
Table 23 shows the access dimension “Affordability”, represented by “PHC expenditure and 
real values per headcount”.  This value includes services and medical products at PHC level. 
. Increasing expenditure per headcount is an indication of supply-side investment from R317 
to R389 towards PHC and ATM at an average 5.7% change from 2013 to 2017.  
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 Table 23 : Supply side dimensions of Access  
 
Source: DHB 2017, GHS 2010, SAHR 2017 
 
3.5.2 Assessing demand-side determinants of ATM  
In order to assess demand–side determinants of ATM, the nationally representative GHS 
2011-2016 data was used and the average sample size over this period was 24 064.   
“Acceptability” was assessed using patient satisfaction as shown in Table 24   About  80% of 
South Africans surveyed in the GHS from 2011 to 2016 were satisfied with the service they 
received at the last visit to a health facility, public or private. There was minimal variation 
around the mean for this measure.  
“Accessibility” was measured by ‘travel time to health facility’. More than 80% of South 
Africans live less than 30 minutes from a health facility and this proportion has been 
increasing over the past 5 years.  The commonest modes of transport to health facilities were 
by foot (49%), taxi (26%) and own transport (20%).  
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In the surveys, respondents were asked if they would use the health facility nearest to their 
dwelling. Approximately 90% of respondents chose a health facility in closest proximity to 
their residence. Of the 10% who do not use the nearest health facility, less than 1% (0.11%) 
cited affordability (too expensive) as the reason.  When asked the reasons for not visiting a 
health facility for recent illness, only 0.08% replied that seeking health services were too 
expensive (unaffordable).  These responses indicate that few people are constrained by 
affordability in seeking healthcare services.   
Two measures of “Availability” were used in this assessment.  The interview question asked 
why respondents would not use their nearest health facility. A small proportion of 
respondents (1.25%) claimed that long waiting times was a deterrent to access and even 
fewer (0.69%) reported that important drugs were not available.   
Table 24 : Demand Side determinants of Access 
Source: Pooled version of GHS 2010-2016 
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CHAPTER 4: DISCUSSION 
 
4.1 Health Policy assessment for Access to Medical Products  
The HSAA framework applied in this study describes the policy landscape for medical 
products and assess the extent of reforms needed to enable ATM.  This study found that 
South African policies hold the necessary actions and intent to achieve universal and 
equitable access to medical products when benchmarked against internationally accepted 
models.  Three distinct policy thrusts emerged in this study - medical products regulation, 
pharmacy practice and health systems strengthening (HSS) which help to understand the 
complex interaction of the health system to produce ATM. This categorisation has utility in 
mapping existing policy and holds appeal to policy makers by highlighting gaps in content 
areas.  Key informants interviewed in this study were well versed in policy and therefore able 
to participate in advocacy, research and consultancy at senior levels in industry, public and 
private health sectors and academia.   
Key informants acknowledged substantial reforms in products regulation and pharmacy 
practice, arising out of the NDP in 1996 but stressed the failure of implementation of these 
well intentioned policies.  The literature review, HSAA assessment and qualitative data 
suggest that HSS efforts have been applied through disparate policies in finance, information 
management, human resource and  service delivery building blocks, and implemented in 
vertical programs, when what is proven effective, is an integrated policy response to create 
synergy around ATM (114).  Key informants identified barriers to ATM  and referred to inter-
sectoral collaboration(133) between public and private sectors and government departments 
and agencies such as  National Treasury, Social Development, Roads and Infrastructure, 
Human Settlements, Trade and Industry, among others, to address the SDH.   
In this environment, the pace of innovation in practice and products, not only dictates policy 
but quickly renders it obsolete.  The literature review and qualitative interviews in this study, 
highlighted two major perspectives - ‘strategic and operational levels ‘in public and private 
sectors.  Over the two decades of NDP implementation, the literature highlights successful 
policy outcomes in medicines pricing and selection, procurement and distribution, rational 
use, harmonisation, financial and human resource deployment, governance and scholarship 
around medical products.  The full extent of gains from key ATM policies is yet to be 
achieved (134)(87), reinforcing  the qualitative theme that many SA governance  frameworks 
and models, although progressive, lack implementation and operational success.   
A number of policy gaps have been identified in this study, such as: medical device price 
regulation; capacity for HTA and pharmacoeconomic evaluations; registration process of 
medical products; uptake of STG/EML across public and private sectors; adverse events 
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reporting of IVDs; rational use of medicines and IVDs in the context of universal coverage 
under NHI, intersectoral collaboration and anticipated regulations arising out of the Medicines 
Act Amendments 2008 and 2015.   
 
4.2 Health financing for Access to medical products  
4.2.1. Public sector expenditure on medical products  
A pivotal contribution of the NDP and other strategic health sector reforms since 1996, was 
to catalyse the commitment towards sustainable public financing of medical products.  The 
paradox of increasing government spending on health and shrinking private sector spending 
in SA over the last decade, as presented in this study, is reassuring that equity and allocative 
efficiency principles are at work.  Econex (118)  suggests that the DOH lacks  efficiency in 
public expenditure  and administration and effectiveness in health outcomes. Bidzha et al 
(132,7) show that public investment  is not sufficient, to improve health  outcomes in SA, 
accounting for SDH and burden of disease while Bletcher et al claim(136) that the 
prioritisation of medicine spending has been one of the DOH’s greatest successes. As 
demonstrated in this study, there has been increased annual spending on medicines (6.7% 
above inflation) from 2005 to 2012, mostly due to the ARV rollout. 
Overall, provinces spent about 6% of the operational budget on medical products.  In 2016, 
the total expenditure on medical supplies in the public sector was estimated at R7.2bn 
(actual R6.7bn based on missing data for MP). . Data quality was a serious concern as 
missing entries for “medical supplies” line items were frequently encountered.  The study 
showed that high disease burden provinces (e.g. KZN, GP and EC) (134, 135) consistently 
lead medical products expenditure at provincial level in the public sector, leaving  NC, LP 
and NW/FS  at the bottom.  Beyond the geospatial, socioeconomic and disease burden 
challenges of these provinces, the absorptive capacity to optimise fiscal resources in  the 
production of health (outcomes and access) is of concern (137).   
At district level, PHC budgets have grown by 4.1% (real per annum) from 2014 to 2016 
driven by HIV in particular and chronic disease spending however PHC headcounts have 
slowed possibly due to the CCMDD but this effect is not quantifiable in the DHIS.  In addition 
to HIV conditional grants, NHI pilot districts received direct NHI conditional grants which were 
not factored into the Provincial budgets. Therefore actual PHC expenditure  may be higher 
than reported in the DHIS, as there are NHI pilots in each province (60). Real PHC 
expenditure per headcount has grown annually between 2005 and 2016 by 6.5%.  
investment in district health services (DHS)  have increased from 35.1% in 1996 to 46.1% of 
total provincial expenditure in 2016 following the shift of the ARV rollout from hospitals to 
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PHC. Consequently, contraction in provincial hospitals and stabilisation of central hospitals’ 
expenditure has been recorded(60), marking the shift towards primary health care.  
In this study private sector expenditure on medical products was shown to outweigh that in 
the public sector by multiples.  Real expenditure on medical products in the public sector is 
lower (about 8% of operational budgets) relative to the private sector through medical 
schemes (15.3%) and when compared to OECD countries (20%)(60). Despite  the paucity of 
data describing disaggregated expenditure in the public sector , Annual Reports of provincial 
DOHs indicate that overall,  medicines and medical supplies consume approximately  11% of 
total budgets (12) at provincial expenditure level.  To further illustrate the point that public 
and private expenditure on medical products is grossly uneven, the provincial and local 
government expenditure per capita in 2016 was R1054 (60) including service fees and 
medical products (138) compared to R2617 (average cost per beneficiary) in the same year 
on medicines alone in the Mediscor sample(58). 
4.2.2 Private sector expenditure on medical products  
Overall in the private sector, the study demonstrated that industry expenditure on medical 
products is exorbitant at  R24bn on medicines only in 2016 covering a population of 8.8 
million members(13) out of the SA population estimated in 2016 at 55 million(139).   
Most medicines were dispensed by pharmacists (89%) and only 5% by GPs, which is easily 
understood  when viewed in context with Mediscor’s sample data(58) showing the dis-
incentivising average differences between claimed (dispensing fee) and approved (scheme 
rate reimbursement) amounts which are lowest for pharmacies (1.8%) and highest for 
GPs(3.3%).  These results bring the debate on what constitutes the professional remit of 
GPs and Pharmacists pertaining to point of care screening, diagnosing, prescribing, treating 
and dispensing, sharply into focus. The qualitative data finds that discussions are already 
underway to expand the scope of Pharmacist services to include collaborative practice, task 
shifting and pharmacy–dependent prescriber arrangements.  
The study results show that 99% more is spent on medical products in private hospitals as 
compared to provincial hospitals, for medical scheme members on low cost options but this 
skewness is due to the huge difference in denominators. In 2016, there were only 549 787 
beneficiaries on low cost options of medical schemes of the total South African scheme 
population of approximately 8.8million (13).  The advent of Efficiency Discount Options 
(EDO), (47 in total in 2016), is based on discounted contributions and network provider 
limitations (i.e. use of designated service providers (DSPs)).  Since gross contribution 
increases in medical schemes are based on numbers of actual principal members plus adult 
and child dependents, there is an opportunity to increase membership through affordable 
member contributions in EDOs.  The health system effect of this is improved access to 
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private healthcare and at a lowered medicines cost by increasing utilisation of provincial 
hospitals(13). 
Medical products expenditure analysed by source of funds, showed that medicine 
expenditure from schemes’ risk funds doubled over 8 years while increases from members’ 
savings more than doubled (2.5 times) in the same period.  There are no known mechanisms 
to ring-fence members’ savings accounts for acute medicines only despite legislation 
(Section 10(6) of Medical Schemes Act) prohibiting their use for PMB medicines. Increasing 
dependence on MSAs as a source of medicines funding without checks and balances is 
problematic as acute, non PMB chronic and OTC medicines attract the highest co-payment 
differentials(58).  In 2015, the CMS implemented a formal process to actively identify the 
sources of OOP for scheme members.  Reports show current estimates of medical scheme 
members’ contributions to total cost of healthcare are around 18.7%, while the scheme 
covers 81.3%, calling into question the ethics of cost sharing. A quarter of all OOP expenses 
in medical scheme members were for medicines(104).  
The average cost per beneficiary on medicines shows a steady increase year on year. The 
average cost of medicines alone in the private sector in 2016 was R150 per item, compared 
to the total average annual cost of OOP medical products expenditure by households in 2014 
(R387) . This unequal spending is indicative of broader societal influences affecting income 
and expenditure disparities in SA(140).  In addition to the spiralling cost of existing drugs, the 
Mediscor data flagged price escalations of NCEs in three years from 2014 to 2017, the 
average cost of these drugs has almost doubled from R555 to R906.   
 
4.2.3 Household level expenditure on medical products  
The LCS 2014 estimated that overall annual household consumption expenditure in SA was 
R1.72 trillion. In 2014/15 the average South African household spent R103 293 and 
proportionally on housing (32.6%), transport (16.3%), miscellaneous goods and services 
(14.7%) and food (12.9%).   Health as a main expenditure group, contributed 0.9 %( R935) of 
total expenditure(126).   
However, health expenditure in these surveys reflects only health services and medical 
products as OOP expenditure by households and does not account for medical aid or 
medical insurance premiums and contributions paid by the household for healthcare.  
Insurance premiums paid by households are captured within the “Miscellaneous goods and 
services” expenditure group. This explains why the average South Africa household 
expenditure appears to be low, averaging 1.34% from 1995 to 2014(126).  Based on average 
household annual income , expenditure on ambulatory healthcare (services and medical 
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products) in SA, is far below the  catastrophic health expenditure threshold of 10-15% of a 
household’s income(140, 141,104).   
In this study, we showed that over the survey periods 2005, 2010, 2008 and 2014, a larger 
proportion of total health spending is on medical products (0.7%) than outpatient medical 
services (0.6%) in average SA households. Within the aggregated medical products 
category, pharmaceutical expenditure dominates (90%) compared to therapeutic appliances 
and other medical products combined, constituting 10%. Overall, the unadjusted means for 
household OOP on medical products was greater in those who were medical scheme 
members than the uninsured households across province, population group, settlement type, 
and income source. Critically, the regression model showed that households without medical 
aid, spent less OOP on medical products than those with medical cover. The province, 
household size and income sources were not significant factors in estimating expenditure for 
members of medical schemes.  For non-members of medical schemes, province (NC and 
LP), and Indian/Asian and White population groups were the only statistically significant 
variables in estimating expenditure in the model.  
In the 2005 to 2014 surveys, the study showed that female headed households spend, on 
average, proportionally more on medical products than male headed households.  However, 
in real (monetary) terms this is reversed; male headed households spend more actual Rands 
on medical products than female headed households.  In 2010, The average household 
income for male-headed households was R151 186, while for female-headed households 
this average was far lower at R70 830(142). 
The addition of the IES 2000 analysis was useful in setting the historical context of 
household medical expenditure. Rural households spent less, both in real terms and 
proportionally on medical products than urban households.  As compared to outpatient 
services, medical products accounted for a larger proportion of the household expenditure on 
health in rural and urban households. The multivariate regression model showed a 
statistically significant effect on rural insured household expenditure; A R31 decrease in 
expenditure for rural insured households was seen for every increase in expenditure by 
urban insured households. However, for non-members of medical schemes, settlement type 
was not a predictor of household expenditure. The differences in the annual expenditure on 
medical products unadjusted means for urban insured and uninsured households was 
R559.9 in 2000.  Vast differences between urban and rural insured households were also 
noted.  
FS, NW, EC and NC provinces had the highest OOP expenditures on medical products. 
Households in LP had the lowest OOP expenditure on medical products in the survey period. 
This result is rooted in the effect of SDH and social deprivation within these provinces. The 
Stellenbosch University https://scholar.sun.ac.za
86 
 
EC province has the highest rate of maternal (52%) and employment deprivation (47.3); NC 
has the highest education deprivation (30%) and LP has the highest rate of living 
environment deprivation (71.9%) in SA. FS, although not the highest, has higher than 
national rates for education deprivation (23.4%).  The regression analysis confirmed that 
province had no significant effect on OOP spending on medical products for members of 
medical schemes, holding all other variables constant. However, two provinces (NC and LP) 
were significantly associated with OOP expenditure for non-insured households.  No reasons 
for the conflicting levels of OOP expenditure in socially deprived provinces of SA were 
advanced in this study, however, this is an important area of future research arising out of 
this work.  Unadjusted means for the survey data in 2000 showed gross disparities in OOP 
expenditure with richer provinces like WC and GP spending more (R175.8 and 178.9 
respectively) compared to LP and NW (R27.3 and R47.4resp).  
Households across the expenditure deciles spent more on outpatient services than on 
medical products. This was most apparent in the highest two expenditure deciles, where the 
expenditure on ambulatory care increases dramatically.  A similar result was obtained when 
analysing income deciles – the differences in expenditure between the lower and higher 
income deciles were inflated at the higher end of the income spectrum.  Despite changes to 
the health system through investment and reform and the effects of inflation and market 
forces, households from the highest expenditure decile spent 36 times more annually on 
medical products than the lowest decile in 2014.   
In 2014, Black/African headed households spent proportionally higher OOP (43%) than 
White headed households(35%) on medicines(126). In 2014 the GHS recorded lowest 
medical scheme coverage in Black/African (10.6%) households as compared to White 
households(76.9%) alluding to the protective  effect of medical scheme membership on   
increases in medicine prices. However, medical scheme membership may not be an option 
for the majority (87,6% of the SA population) of Black/Africans who, in 2014, earned  less 
than R71 479per annum (lower limit of upper income quintile) and almost half (48%) of whom 
were in quintile 1 and 2(126). The regression model predicted statistically significant 
increases in OOP spending by Indian/Asian and White population groups as compared to 
Black/African population group in 2000. Also in 2000, White households who were insured 
spent 30 times more OOP than insured Black/African households on medical products.  
4.3 Health Systems Strengthening for Access to Medical Products  
This study shows that most South African households have access to healthcare services 
and live sufficiently close to health facilities so that they are able to access the facilities by 
foot.  PHC utilisation rate  is increasing in SA  and is used here as a proxy measure  for 
accessibility(143)  although its  multidimensional complexity  includes other factors such as  
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family education level,  financial status,   perception of health and cultural beliefs(140, 56). In 
the private sector, access to healthcare is facilitated by financial risk protection mainly 
through insurance and medical aid.  In 2016, medical scheme members visited GPs an 
average of 3.6 times per year (2016) (13); below WHO recommendation of 5 visits per year 
and above the current public sector PHC utilization rate of 2.3 times in 2016.  For every 1000 
members, a GP was consulted 731 times(13). Inpatient utilisation in private is 180 per 1000 
scheme members in 2016, exceeding WHO recommendations  of 10-15 hospital discharges 
per 100 population (11,139).  
The results show that availability of medicines is a persistent challenge to effective PHC and 
ATM in SA.  The literature and qualitative interviews confirm that there are serious 
disruptions to the medical products supply chain which impact quality of care and ATM.   
Three provinces with the highest number and longest duration of stock-outs in the SSOP 
study in 2015 were MP, FS and GP, which incurred the highest expenditure on medicines 
(10.6%, 7.5% and 8.1% respectively) in 2013 as reported in this study, beyond the median 
expenditure for all other provinces (6.9%) underscoring serious deficiencies in provincial 
supply chain management.   
Affordability of medical products is achieved through supply-side mechanisms ensuring 
sustainable financing and investment in PHC expenditure.  The relationship between 
expenditure, service delivery and performance, may not be directly correlated and  is  
dependent on more than funding alone (137).  This study shows that district health services 
and PHC expenditure per headcount is equitably financed to drive access to healthcare.  
HIV/AIDS is a driver of PHC expenditure. HIV/AIDS expenditure increased by 38% (8.4%) 
per annum in real terms over past 5 years, while non-HIV PHC expenditure has increased by 
13% (3%) per annum(136).  The CCMDD programme has decreased the PHC headcounts 
by decanting patients from PHC facilities and thus impacted PHC expenditure per 
headcount(60) while improving ATM.  
The study results show that only half of the patients using the public sector, find the service 
acceptable. The reasons for this low acceptability must be addressed as it affects access to 
healthcare and ATM.   
Overall, from this analysis of demand side determinants, there is stable progress towards 
ATM in SA from 2011 to 2016.  The supply-side analysis shows that while there is 
achievement in accessibility through infrastructure and affordability through PHC investment, 
urgency is needed to address availability and acceptability of ATM in SA. 
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CHAPTER 5: CONCLUSION AND RECOMMENDATIONS 
 
5.1 Conclusion 
Pharmaceutical regulatory framework in South Africa is vast and encompasses the key 
elements needed to implemented health systems changes for access to medicines.  The 
reforms have been extensive and have had far reaching effects. Expenditure in both private 
and public sectors on medical products, is increasing but not comparable.  Despite 
substantial progress in ATM there are supply-side issues needing urgent response such as 
drug availability and quality of care in the public sector and the rising cost of OOP payments.   
The legacy of entrenched divisions in the population infiltrates all levels of the health system, 
affecting resource allocation and impacting supply and demand side determinants of access 
to care. Equity and ATM forms a positive reinforcing loop and to interrupt this cycle health 
system stakeholders must actively address the differences between urban and rural, high 
and low income quintiles, men and women, PHC and secondary hospitals and interprovincial 
(e.g. WC and LP) differences in ATM.  In this study, supply side factors are shown to 
exacerbate inadequate access to medicines and qualitative data suggest that these are 
amenable to change through operational efficiencies.  
Demand side determinants stem from deeply rooted inequalities in socioeconomic status, 
human settlement education and cultural practices; which require political will, resources and 
social mobilisation.   
The strategic importance of South Africa for the pharmaceutical and medical devices sector, 
is a leverage point for South African policymakers to facilitate harmonizing efforts to build 
capacity in regional health systems.  This study has broad implications for health systems in 
LMICs in SSA embarking on reforms to embrace changes that the global pharmaceutical and 
health technology supply chain impose.   
The contribution of this study was the mixed methods design to capture the complexity of the 
health system and add new ways in HSPR to explore multifaceted issues, such as ATM, with 
pragmatic significance.  This study therefore moves beyond analysis of ATM, to create a 
synthesis of information, uniting disparate sources of data.   
Significantly, a major contribution of this study, is the extent to which new insights can be 
drawn from publicly available and routinely collected data. Indeed, all sources of secondary 
data used in this study are in the public domain.  This study advances the synthesis of 
varying sources of data to reflect health system complexity and thus contributes to the 
methodological diversity of HPSR in SA.  
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5.2 Limitations 
This study did not involve the use of analytical tools or techniques routinely used in 
economics sciences. Therefore calculations performed are not adjusted for headline or 
health inflation and do not account for exchange, real and nominal rates.   
The multiple regression was used in this study to explore the relationship between household 
OOP expenditure on medical products and a number of demographic independent variables 
of interest.  This regression analysis ignores the asymmetry of response distributions 
common with expenditure data and the large mass of observations with zero cost. Therefore 
further bio statistical analyses are recommended to study the effects of the factors on the 
model.  
Public sector expenditure at PHC and hospital level allocated to service areas is not easily 
accessible and do not form part of statutory reporting requirements yet programmatic 
budgeting will facilitate economic analyses and costing studies.  Disaggregated expenditure 
data for public sector is not available and where data is in the public domain, there are 
serious challenges with the quality, comparability and consistency. 
Data in provincial Annual reports based on BAS is inconsistent and threatens reliability of 
inter-district or provincial comparison.  This is often caused by misclassification of goods and 
services in the BAS system.  An example of this is misclassification of expenditure line items, 
reported in the NC Annual Financial Statement Report disclosure notes (2012).   
Cumulative effects of access to care and expenditure on healthcare comparisons were 
drawn from annual household surveys but do not capture the effects of intervening events 
such as illness, trauma on health and disability.  
The contribution of industry suppliers and manufacturers to stocks-outs and therefore ATM 
was not explored in this study.  
In-depth analysis from an economics perspective on private and public sector expenditure 
requires microdata and is an entirely separate pursuit, larger than the scope of this project. 
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5.3 Recommendations 
These recommendations are based on quantitative and (mainly) qualitative data presented in 
this study.  
 Policy makers in SA have a unique opportunity to institute reform in the scale up to 
UHC. Innovative pricing models, public private partnerships, sustainable financing 
and delivery of services and increased investment in health technology are some of 
the policy options to increase ATM.  
 Supply side availability of medicines has not been realised despite pressure to 
perform in this area.  Civil society has been actively engaged around the human 
rights’ aspects or lack of access to medical products however, clinic committees 
(PHC level) and hospital Boards (hospital level) and Ward councillors are key 
resources yet to be mobilised effectively as a push factor for political accountability.   
 Medical schemes and MCOs drive provider behaviour motivated by cost containment 
and profit maximisation, using mechanism such as preferred provider networks, 
payment incentives and performance rating.  The CMS Circular 13 of 2014 (150), 
which defines and clarifies the scope of managed care services, in their role as 
facilitators of appropriate and cost-effective ‘relevant’ (150) healthcare services. 
Funders in SA therefore have the mandate to pursue more enterprising and 
sustainable goals such as access, equity and quality in the private sector which 
promotes ATM within a broader clinical governance agenda. 
 Capacity building of healthcare managers within the district and provincial 
management echelons is needed to ensure equitable fiscal allocations, absorption of 
financial resources which translate into optimised service delivery, without which, 
ATM cannot be realised. This can be achieved through the enforcement of a 
legislative framework, such as those reforms currently proposed under the NHI 
Scheme, that provides for sustainable financing, access, quality and equity.  
 As a prelude to the NHI, enhanced strategic information management capacity to 
monitor cost and utilisation of medicines and medical devices at health facilities and 
evaluate cost effectiveness of health technologies.  As a first step, tracking this 
information through existing SCM platforms, will be necessary to manage the supply, 
use and control of medical products.  
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Annexure A: SA Regulatory map Part 1  
Table 25 : SA regulatory landscape Part 1 
 
Source: Author  
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Annexure B: SA Regulatory map Part 2 
Table 26 : SA Regulatory landscape Part 2 
Source: Author 
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Annexure C: Regression table -Private sector 
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Annexure D: Regression table -Public sector 
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